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Abstract
Sepsis, severe sepsis, and septic shock are stages of a medical emergency char-
acterised by an intensifying whole-body immune response to infection leading to
organ dysfunction, shock, and ultimately death. Importantly, these stages do not
represent an intensifying infection, but rather the body’s intensifying immune re-
sponse to infection. Yet, despite advances in modern critical care medicine, sepsis
remains common, increasingly costly, and often deadly.
Time to initiation of effective antimicrobial therapy following sepsis-induced
hypotension (i.e. septic shock) is the single strongest predictor of outcome over
any form of treatment. Furthermore, early treatment reduces sepsis mortality.
Importantly, a challenge in the early identification of sepsis is that infection is
not always clinically evident. Gold standard blood culture microbiological results
return only in retrospect with significant delay. Additionally, there are no bio-
chemical and immunological biomarkers with sufficient performance for routine
use in critical care. Finally, protocolised categorisation using the ACCP/SCCM
sepsis definitions in real-time is erratic and often reflects misclassification, het-
erogeneous categorisation, and exclusion. Thus, there remains a serious need for
early, accurate, time-dependent, patient specific diagnostics for sepsis available
at the bedside in real-time for clinical decision support.
Mathematical models of physiology developed from clinical data can identify
patient-specific parameters, in particular, model-based insulin sensitivity (SI),
which is related to patient condition and sepsis state. A multivariate biomarker
has been shown to link model-based SI and clinical measures to septic shock.
This thesis further develops a model-based sepsis diagnostic for severe sepsis
from model-based SI , temperature, heart rate, respiratory rate, blood pressure,
and SIRS score. Study data was obtained from patient records of 36 adult sep-
sis patients in the Christchurch Hospital ICU, where the ACCP/SCCM sepsis
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definitions were used to categorise hourly sepsis state, resulting in 213 hours of
severe sepsis and septic shock cases and 5858 hours of SIRS and sepsis controls.
Kernel density estimates (KDE) using the Bayes classifier were used to esti-
mate class conditional joint probability density profiles of the clinical predictors
and for classification. The unknown patient hour to be classified was tested
against these established datasets, with the result being a classification into ei-
ther the case or control group. The classifier performed with the greatest sta-
bility and accuracy when using the product kernel, 0.5 prior probabilities, and
Cholesky transformation. Optimal diagnostic performance from the receiver op-
erating characteristic (ROC) curve was determined as 0.78 (0.69–0.94) sensitiv-
ity, 0.83 (0.76–0.94) specificity, 0.87 (0.78–0.99) AUC, 0.10–0.36 PPV, 0.99–1.00
NPV, 4.48 (2.88–15.70) LHR+, 0.27 (0.06–0.41) LHR-, and 16.83 (7.04–262) DOR
at an optimal posterior probability cutoff value of 0.31. Thus, kernel implemen-
tation of the Bayes classifier given bedside clinical measurements can provide a
useful posterior probability for clinical decision making in real-time.
An independent classifier was developed whereby the ACCP/SCCM classi-
fication criteria were independently evaluated and summed, providing a 25.8%
disease prevalence (1690 of 6550 hours). Similarly, the KDE estimation and clas-
sification method was used, resulting in optimal diagnostic performance of 0.86
(0.81–0.94) sensitivity, 0.85 (0.79–0.95) specificity, 0.92 (0.88–0.99) AUC, 6 (4–18)
LHR+, 0.17 (0.06–0.24) LHR-, 0.57–0.86) PPV, 0.92–0.98) NPV, and 34 (16–300)
DOR at an optimal posterior probability cutoff value of 0.49. The diagnostic re-
sults show high accuracy as a potential severe sepsis diagnostic and monitoring
response to sepsis interventions in real-time. Thus, relaxation of the hierarchical
and concurrent criteria in the ACCP/SCCM definitions captured the more staged
and clinically observed evolution of sepsis over time, including plateaus of septic
shock treatment during administration of IV fluid resuscitation. Therefore, it is
an improved, objective metric especially for real-time diagnosis and monitoring
of response to disease and treatment.
A hidden Markov model (HMM) was developed to link observed clinical mea-
surements to unobserved sepsis states and to include time-dependency. A HMM
topology was defined to represent the study variable relationships, given the
observed time series of physiological variables. In particular, the topology de-
fines transitions for the hidden states and the distributions of the observations
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conditioned on each hidden state. Thus, the labelled data can be used to es-
timate the transition probabilities of the hidden sepsis states. The conditional
distributions, P (observation—sepsis state), were found using the joint proba-
bility densities using kernel density estimates. Finally, the hidden states were
estimated by determining the most probable path of the joint probability of the
observed sequence and the hidden sequence. Upon determining the posterior
probability of a patient sepsis state, the patient hour is compared against the
established dataset and diagnostic performance from the ROC curve was deter-
mined for resubstitution, repeated holdout estimate, and leave one out estimate.
The HMM performed with 0.59–0.95 sensitivity, 0.61–0.96 specificity, 1.54–23.96
LHR+, 0.05–0.66 LHR-, 0.63–0.99 AUC, and 2–474 DOR. The state transition
probabilities were shown to be independent of sepsis categorisation definitions.
Furthermore, the observed clinical signs are linked to hidden sepsis state, yet
are most accurate when the model is trained on the patient data. Thus, the
HMM has the most potential as a real-time, patient-specific model to reduce the
variability of diagnosis due to inter- and intra-patient variability.
Overall, this thesis develops and characterises a range of model-based metabolic
biomarker linked sepsis diagnostics. The analysis of their efficacy is taken to a
statistically valid level not typically seen in the medical literature and provides
significant new insight into how diagnosing sepsis is affected by prevalence and
lack of clarity in the specific criteria used. The diagnostics created are all novel
for their real-time, hour-to-hour approach compared to the typical multi-hour or
daily evaluation typically used that provides detection only with significant delay.
Thus, the approach itself offers new potential. The sum of this work provides
a significant step forward and clear foundation from which to develop objective,
automated, real-time sepsis diagnostics, a prototype for clinical validation, as
well as providing significant new insight into sepsis, its diagnosis and how it is
viewed clinically.

Chapter 1
Introduction
1.1 Epidemiology
Sepsis is a common, deadly, and costly medical emergency requiring early hospi-
talisation and treatment intervention. Sepsis is becoming increasingly common
as a principle diagnosis for hospitalisation with increasing incidence afflicting an
ageing population [Lagu et al., 2012; Martin, 2012]. Sepsis patients are more
severely ill than patients hospitalised for another diagnosis, stay longer in hospi-
tal than other inpatients, and are more expensive to treat than other patients.
Sepsis patients are also more likely to die than other patients. As a primary diag-
nosis, sepsis accounted for 2% of hospitalisations in the US in 2008, yet made up
17% of in-hospital deaths [Hall et al., 2011]. New Zealand and Australian sepsis
mortality was 18.4% in 2012 [Kaukonen et al., 2014]. Table 1.1 summarises and
puts specific values to these epidemiological statistics.
Table 1.1: Sepsis epidemiology from Hall et al. [2011]. These statistics are for hospi-
talisations of sepsis as a primary diagnosis in the US in 2008. Where applicable, the
figures provided are distinguished by age groups (a: 65+ years old and b: 65- years
old) or in comparison to hospitalisations for other diagnoses.
Incidence: 24.0 incidence per 10,000 in 2008 (11.6 per 10,000 in 2000)
ICU prevalence: 20% prevalence in the medical ICU [Alberti et al., 2002]
Age: 2/3 of sepsis patients are aged 65+ (122.2a and 9.5b per 10,000)
Comorbidity : 26%a and 200%b as likely to have seven or more diagnoses
Length of stay : 75% longer (43%a and 200%b longer LOS)
Mortality : eight times as likely (20%a and 13%b mortality)
Cost : $14.6B (11.9% annual inflation-adjusted increase since 1997)
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1.2 Sepsis
A local infection activates the body’s natural defence mechanism, the inflam-
matory response. The cardinal signs of the immune response are: calor (heat),
rhubor (redness), tumor (swelling), and dolor (pain). These symptoms are due to
changes in the local blood vessels that expand, to become more permeable, due to
increased blood supply. These changes allow immune cells to penetrate through
the vascular walls and enter the tissues to remove the pathogens. In addition,
the blood in neighbouring micro-vessels coagulates to keep the invading pathogen
isolated from the circulatory system. However, if the immune system is weak-
ened or the infection is particularly severe, such a local infection can overcome
the body’s natural defence mechanisms and spread throughout the body.
A local infection can be diagnosed as sepsis when these defence mechanisms
fail and pathogens enter and travel through the circulatory system. The result is
that the ongoing and intensified process of inflammation becomes widespread in
the body. Sepsis is thus, in part, a whole-body inflammatory response to infec-
tion. Sepsis may subsequently or simultaneously lead to damage to organs and
tissues that have not yet been invaded directly by pathogens, leading, unchecked,
to subsequent organ failure and possibly death.
Thus, a negative impact of this overwhelming whole-body inflammatory re-
sponse to infection causes organ failure. In severe sepsis cases, the function of
individual organs starts to deteriorate and may completely fail. Blood clots form
around organs and in peripheral vessels, and the reduced blood flow deprives
the limbs and internal organs of nutrients, oxygen supply, and the transport of
wastes, further deteriorating function. In addition, the heart races, the kidneys
no longer produce urine, and the patent’s mental status can become gravely im-
paired. The patient’s life is thus in acute danger. Emergency medical treatment,
including organ support, antimicrobials, and intravenous fluids are required to
restore circulatory function and remains the only hope for survival.
Finally, an individual organ failure may lead to sequential or simultaneous
organ failure. In addition, failure of the cardiovascular system leads to a life-
threatening drop in blood pressure, called septic shock. Septic shock may lead
to death, especially if it is not recognised and treated early with circulatory
support. Each major organ failure causes further subsequent problems for the
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body in managing the infection and maintaining other organ function. It is thus
a cascade of effects.
Overall, sepsis is thus an acute inflammatory response to infection. In more
severe cases it includes major organ failure. Each subsequent effect in this cascade
of increase in severity of this response significantly increases the risk of death.
Broad reviews of sepsis concepts, pathophysiology, and treatment in adults are
provided by Angus and Van Der Poll [2013] and in neonates by Shane and Stoll
[2013].
1.3 Prevention
The cause of sepsis is always infection. Infection is most commonly caused by
bacteria, but also viruses, fungi, or single-celled parasites. If infection cannot
be contained by the body’s immune system, infection in the lungs (pneumonia),
bladder and kidneys (urinary tract infection), and primary bloodstream infection,
abdomen (peritonitis), skin (cellulitis), and other areas (meningitis) can lead to
sepsis. It has been reported that the respiratory, digestive, urinary tracts, and
primary blood-stream infections represented about 80% of all source infection
sites [Alberti et al., 2002]. Abdominal infections, bloodstream infections, and
fungal infections have been observed to be more likely associated with septic
shock [Alberti et al., 2002]. Therefore, sepsis can be best prevented and managed
by prevention or effective and early management of infection.
Yet, despite advances in modern medicine, there are increased hospitalisa-
tions for sepsis, primarily due to an ageing population with more chronic illnesses,
greater use of invasive procedures, prolonged use of preventative immunosuppres-
sive drugs, chemotherapy, immune suppression for organ transplantation, overuse
of antibiotics, and increasing antibiotic resistant organisms [Angus et al., 2001].
More simply, an ageing population is more at risk for sepsis due to a naturally
weakened ability to fight off infection. Thus, sepsis is evident in a variety of epi-
demiological and clinical issues that remain poorly understood and managed by
healthcare systems under increasing economic and demographic stress, including
the optimal delivery of care for vulnerable and elderly populations [Angus et al.,
2001].
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1.4 Classification
The American College for Chest Physicians/Society of Critical Care Medicine
(ACCP/SCCM) Consensus Conference was held in 1991 with the goal of agree-
ing on a set of definitions that could be applied to patients with sepsis and its
sequelae. Broad definitions of sepsis and the systemic inflammatory response
syndrome were proposed, along with detailed physiologic parameters by which a
patient may be categorised. Definitions for the systemic inflammatory response
syndrome (SIRS), sepsis, severe sepsis, and septic shock are provided below.
These general definitions have been widely used in practice, and have served as
the foundation for inclusion criteria for clinical trials and therapeutic interven-
tions.
The systemic inflammatory response syndrome (SIRS) is defined as two or
more of the following conditions [Bone et al., 1992; Levy et al., 2003]:
• Temperature > 38◦ C or < 36◦ C
• Heart rate > 90 beats per minute
• Respiratory rate > 20 breaths per minute or PaCO2 < 32 mmHg
• White blood cell count 12, 000/cu mm, < 4, 000/ cu mm, or > 10% imma-
ture (band) forms
Sepsis is then defined as SIRS due to infection [Bone et al., 1992; Levy et al.,
2003]. It thus requires SIRS and evidence of infection.
Severe sepsis is defined as sepsis associated with organ dysfunction, hypop-
erfusion, or hypotension [Bone et al., 1992; Levy et al., 2003]. Septic shock is
defined as sepsis-induced hypotension, defined as a systolic blood pressure < 90
mmHg or a reduction of ≥ 40 mmHg from baseline, despite adequate fluid resus-
citation, along with the presence of perfusion abnormalities [Bone et al., 1992;
Levy et al., 2003]. Table 1.2 shows the detailed physiological parameters used
to define sepsis, while Table 1.3 details the clinical signs that define severe sepsis.
Thus, these conditions and their physiological presentation represent sepsis as
a continuum of severity concerning both infectious and inflammatory components,
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Table 1.2: Diagnostic criteria for sepsis (from Bone et al. [1992] and Levy et al.
[2003]).
Infection. Documented or suspected and some of the following:
General parameters. Fever (core temperature > 38.3◦ C), Hypothermia (core tem-
perature < 36◦ C), Heart rate > 90 beats/min or > 2 SD above the normal value
for age, Tachypnea (> 30 breaths/min), Altered mental status, Significant edema
or positive fluid balance (> 20 ml/kg over 24 h), Hyperglycemia (plasma glucose
> 110 mg/dl or 7.7 mM/l) in the absence of diabetes
Inflammatory parameters. Leukocytosis (white blood cell count > 12, 000/µl),
Leukopenia (white blood cell count < 4, 000/µl), Normal white blood cell count
with > 10% immature forms, Plasma C reactive protein > 2 SD above the normal
value, Plasma procalcitonin > 2 SD above the normal value
Hemodynamic parameters. Arterial hypotension (SBP < 90 mmHg, MAP < 70, or
a SBP decrease > 40 mmHg in adults or < 2 SD below normal for age), Mixed
venous oxygen saturation > 70%, Cardiac index > 3.5 l/min/m2
Organ dysfunction parameters. Arterial hypoxemia (PaO2/FIO2 < 300), Acute olig-
uria (urine output < 0.5 ml/kg/h or 45 mM/l for at least 2 h), Creatine incease ≥ 0.5
mg/dl, Coagulation abnormalities (international normalised ratio > 1.5 or activated
partial thromboplastin time > 60 s), Ileus (absent bowel sounds), Thrombocytope-
nia (platelet count < 100, 000/µl), Hyperbilirubinemia (plasma total bilirubin > 4
mg/dl or 70 mmol/l)
Tissue perfusion parameters. Hyperlactatemia (> 3 mmol/l), Decreased capillary
refill or mottling
as well as subsequent organ failure. If definable phases exist on a continuum
of severity, populations could be characterised for increased risk of mortality
and independent prognostic implications along the same scale. Therefore, this
standardisation of terminology allows communication amongst researchers and
clinicians to compare protocols and evaluate therapeutic interventions.
1.5 Diagnostics
There does not yet exist an adequate gold standard diagnostic test for sepsis.
In particular, while SIRS is well defined and objective, the presence of infection
can be difficult to detect consistently. Blood culture provides microbiological
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Table 1.3: Severe sepsis definition (from Bone et al. [1992] and Levy et al. [2003]).
Severe sepsis definition = sepsis-induced tissue hypoperfusion or organ dysfunction
(any of the following thought to be due to the infection):
Sepsis-induced hypotension, Lactate above upper limits laboratory normal, Urine
output < 0.5 mL/kg/h for more than 2 h despite adequate fluid resuscitation, Acute
lung injury with PaO2/FiO2 < 250 in the absence of pneumonia as infection source,
Acute lung injury with PaO2/FiO2 < 200 in the presence of pneumonia as infec-
tion source, Creatinine > 2.0 mg/dL (176.8 µmol/L), Bilirubin > 2 mg/dL (34.2
µmol/L), Platelet count < 100, 000µL, Coagulopathy (international normalised ratio
> 1.5)
documentation of the presence of invading pathogens in the blood. However,
this evidence is not sufficient for a positive diagnosis of sepsis, as these culture
tests can yield both false positive and false negative results. Alternatively, the
ACCP/SCCM sepsis definitions use positive blood culture plus clinical signs of
infection as a positive gold standard, and negative blood culture without clinical
evidence as the negative gold standard. Thus, the ACCP/SCCM sepsis defini-
tions instead provide a clinical documentation of sepsis, which aims to charac-
terise various stages of the associated inflammatory response and to differenti-
ate infectious from non-infectious processes [Bone et al., 1992; Levy et al., 2003].
However, such clinical evidence is subjective and depends on experience.
Importantly, the usefulness of the ACCP/SCCM definitions has been chal-
lenged, because it requires microbiological documentation of infections, which
is available only in retrospect, and because some patients with definite infec-
tion do not fulfil criteria for any of the sepsis categories [Alberti et al., 2002;
Brun-Buisson, 2000]. In an epidemiological study, Alberti et al. [2002] found
that one-fifth of long-stay, more than 24 hours, patients with infection in the
ICU did not fulfil criteria for any sepsis categorisation. Additionally, 80% of
the clinically documented infections were classified in sepsis categories, of which
one-half had manifestations of either severe sepsis or septic shock [Alberti et al.,
2002]. Thus, the ACCP/SCCM classifications categorise ICU patients into het-
erogeneous populations, which reflects the fact that sepsis represents a clinical
syndrome and not a specific single disease [Alberti et al., 2002].
Therefore, using the ACCP/SCCM classification as an entry criterion in clin-
1.6 TREATMENT 7
ical trials can be deceptive as many cases may be missed or poorly diagnosed.
The authors themselves note that clinical trials include highly selective patient
populations and thus the global epidemiology of infection encountered in the
ICU can hardly be accurately derived from these studies [Alberti et al., 2002].
Additionally, the ACCP/SCCM definitions exclude non-documented infections,
thus eliminating nearly one-half of patients with community acquired infection -
a major problem for evaluation of new therapeutic agents, treatment approaches,
and diagnostics [Alberti et al., 2002].
A more useful sepsis biomarker would help identify or rule out sepsis, and
should also be able to guide therapy. More than 170 different biomarkers have
been assessed for potential use for molecular diagnostics in sepsis, primarily as
prognostic markers, while only ten have been used for diagnosis [Pierrakos et al.,
2010]. C-reactive protein (CRP) and procalcitonin (PCT) have been most widely
used [Wacker et al., 2013; Kibe et al., 2011], but both have limited ability to dif-
ferentiate sepsis from other non-infectious causes of SIRS [Giamarellos-Bourboulis et al.,
2004]. No biomarker, therefore, has established itself sufficiently to be of great
help to clinicians in everyday clinical practice [Pierrakos et al., 2010]. So, the
search still continues for potential sepsis biomarkers [Reinhart et al., 2012; Parlato and Cavaillon
2015], including combinations of potential biomarkers [Gibot et al., 2012].
Thus, the timing for early sepsis diagnosis is delayed because clinical and lab-
oratory signs used are not specific enough. In addition, sepsis is under-recognised
and poorly understood due to confusion about its definition, lack of documenta-
tion of sepsis as a cause of death, inadequate diagnostic tools, and inconsistent
application of standardised clinical guidelines to treat sepsis. Thus, there remains
a serious need for improved sepsis diagnostics for the improvement of survival in
sepsis patients.
1.6 Treatment
Intensive care medicine provides the necessary diagnosis, management, organ
support, and monitoring for sepsis patients. Yet, despite modern medicine, sepsis
mortality remains high. In particular, epidemiological studies have shown 16.9%
ICU mortality in non-infected patients, is contrasted by 53.6% mortality in sepsis
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patients [Alberti et al., 2002], signifying a significant leverage point and need.
Effective treatment in the ICU requires early antibiotic administration and
intravenous (IV) fluids after diagnosis. Broad-spectrum antibiotics delivered in-
travenously are effective against several common bacteria, while a physician may
prescribe a specific type of antibiotic based on the type of infectious organism,
when it is known or strongly suspected. IV fluids are administered to prevent hy-
potensive shock, support organ function, and reduce damage from sepsis. Future
developments in treatments may focus on host immunomodulation [Wiersinga,
2011; Hotchkiss et al., 2013].
Importantly, Kumar et al. [2006] determined that the time to initiation of
effective antimicrobial therapy following sepsis-induced hypotension (i.e. septic
shock) is the single strongest predictor of outcome over any form of treatment
[Kumar et al., 2006]. Antimicrobial administration within the first hour of docu-
mented hypotension was associated with a survival rate of 79.9% [Kumar et al.,
2006]. Yet, after four hours, the survival rates were as low as 50% [Kumar et al.,
2006]. Thus, each hour in delay of treatment was associated with an average de-
crease in survival of 7.6% [Kumar et al., 2006]. Given that the observed median
time to antimicrobial therapy was 6 hours, the high mortality rates are not too
surprising [Kumar et al., 2006]. The current clinical reality is that sepsis is still
often overlooked and recognised too late; and there is thus, from these results, a
clear need for a rapid and accurate real-time diagnostic.
The Surviving Sepsis Campaign (SSC) has provided international guidelines
for the management of severe sepsis and septic shock [Dellinger et al., 2013].
Besides the ICU, these guidelines can also be implemented in the Emergency
Room setting [Nguyen et al., 2006]. In particular, the SSC guidelines provided a
core set of bundles specifying physiological resuscitation targets to be completed
within three hours and six hours after recognition. Thus, these bundles are
recommendations for hospital behaviour and are then used as the basis to measure
the impact on sepsis treatment programs. Results of compliance with bundle
targets and association with hospital mortality showed that unadjusted hospital
mortality decreased from 37 to 30.8% over two years, and an adjusted absolute
drop of 5.4% over 2 years [Levy et al., 2010]. These results are consistent with
the observation that early diagnosis and effective treatment lead to improved
survival.
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1.7 Summary
Sepsis is a common, deadly, and costly syndrome afflicting immune compromised
and elderly populations which presents as a cascade of infectious and inflam-
matory processes leading to life-threatening organ failure. Yet, there are no
established criteria and biomarkers due to the heterogeneity of the host patho-
physiological processes. However, early treatment and management has clearly
indicated that early diagnosis allowing effective treatment significantly improves
survival. Therefore, the problem is that there remains a serious need for early and
accurate sepsis diagnostics, which are necessary to initiate life-saving treatment
for sepsis patients in real-time, rather than retrospectively.

Chapter 2
Background
2.1 Sepsis diagnostics
Simply put, a diagnostic test for sepsis would be regarded as successful, beyond
current practice, if clinicians and researchers consider it as helpful in identifying
sepsis. In particular, clinicians require an early and accurate diagnostic available
at the bedside to allow early treatment, which is critical for patient survival
[Kumar et al., 2006]. Additionally, an established criteria would allow researchers
to compare the effectiveness of new and current therapeutics, and to optimise
treatments. However, there remains no established gold standard diagnostic test
for sepsis.
Current diagnostic approaches rely on some combination of clinical, micro-
biological, biochemical, or immunological findings, some of all of which may in-
dicate the presence of infection or host response to infection. For example, the
ACCP/SCCM criteria [Bone et al., 1992; Levy et al., 2003] uses clinical signs of
inflammation, likely due to immune response, and microbiological evidence to
define sepsis. However, these criteria have been developed based upon subjective
clinical observations and, importantly, blood culture confirmation is only available
in retrospect with significant delay. In addition, 178 different biochemical and im-
munological biomarkers have been studied for sepsis diagnostics [Pierrakos et al.,
2010], yet none achieve clinically significant performance. Thus, there remains a
serious need for an early and accurate sepsis diagnostic test for patient survival
in critical care.
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2.2 Related work
Although limited, the ACCP/SCCM definitions [Bone et al., 1992; Levy et al.,
2003] are the most widely used sepsis criteria. The consensus definitions were
based upon clinical bedside experience and introduced as a standardisation of
terminology. Generally, the criteria conceptualise the sepsis syndrome as a pro-
gressive and injurious inflammatory response to infection leading to organ failure,
a life-threatening drop in blood pressure, and ultimately death. Notably, the cri-
teria continue to evolve along with a growing understanding of the pathology of
sepsis and its sequela.
SIRS is defined as the systemic inflammatory response syndrome, which in-
volves host temperature, heart rate, respiratory rate, and white blood cell count
[Bone et al., 1992; Levy et al., 2003]. Notably, SIRS is defined by simple clini-
cal measurements, rather than biochemical or immunological findings. However,
SIRS is not specific enough to identify sepsis or to identify a distinct pattern in
the host response to infection [Marshall, 2000; Vincent, 1997], as these clinical
signs have many alternative causes in the critically ill patient.
Sepsis is formally defined as SIRS due to infection [Bone et al., 1992; Levy et al.,
2003]. However, it is important to note that microbiologic confirmation of infec-
tion is only available in retrospect, as blood culture test results return in 24–48
hours. In addition, tests yield both false positive and false negative results, where
there is a great deal of ‘culture negative’ sepsis that did not grow in vitro. Thus,
it remains a challenge to determine if SIRS is due to infection rather than another
cause. Therefore, the clinical reality of the ACCP/SCCM criteria is that they
can only best describe when a patient ‘looks septic’.
Finally, severe sepsis, a sepsis subset, is defined as organ dysfunction due to
sepsis and septic shock is defined as hypotension due to sepsis (see Table 1.2)
[Bone et al., 1992; Levy et al., 2003]. Severe sepsis is important as it segregates
a particular, more severely ill group with higher morbidity and mortality. Organ
dysfunction is defined by the multiple organ dysfunction syndrome (MODS) as-
sessment score [Marshall et al., 1995] or the sequential organ failure assessment
(SOFA) score [Vincent et al., 1996]. Importantly, the first symptoms observed
by a clinician that would initiate an assessment of sepsis at the bedside would be
symptoms indicative of early organ dysfunction. Thus, the initiation of sepsis di-
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agnostics occurs later in the sepsis syndrome more towards severe sepsis, namely,
when a patient requires organ support in the ICU or has a life threatening drop
in blood pressure.
The ACCP/SCCM criteria will necessarily expand the list of signs and symp-
toms to reflect the clinical experience of symptoms at the bedside. However, it is
notable that in the time of over a decade between Bone et al. [1992] to Levy et al.
[2003], there has been no evidence to support any changes in these definitions.
This lack of evidence underscores the challenges still present in distinguishing
sepsis from other inflammatory processes and identifying the clinical, microbio-
logical, immunological, and biochemical markers useful for diagnosis.
2.3 Remaining challenges
Ultimately, the ACCP/SCCM definitions codify the physical and laboratory find-
ings that prompt an experienced clinician to conclude that an infected patient
‘looks septic’. However, in clinical practice, application of the SIRS, sepsis, severe
sepsis, and septic shock definitions do not properly categorise and stage patients.
In particular, the ACCP/SCCM classifications categorise ICU patients into het-
erogeneous populations, which reflects the fact that sepsis represents a clinical
syndrome and not a disease [Alberti et al., 2002].
For example, the sepsis definitions can omit patients with infection from clas-
sification. An epidemiological study found that one-fifth of patients with infection
in the ICU for over 24 hours did not fulfil criteria for any sepsis categorisation
[Alberti et al., 2002]. Thus, Alberti et al. [2002] argues that identifying infections
overall is important, not just sepsis and sepsis-related conditions, a classification
which eliminates about one-fifth of infections.
The ACCP/SCCM definitions require microbiological documentation of in-
fection [Bone et al., 1992; Levy et al., 2003]. Yet, 20% of patients with confirmed
infection still did not fulfil criteria for any of the sepsis categories [Alberti et al.,
2002; Brun-Buisson, 2000]. Also, 80% of patients with clinically documented in-
fections where classified into sepsis categories, yet half of these patients had man-
ifestations of either severe sepsis or septic shock [Alberti et al., 2002]. Therefore,
the usefulness of the criteria has been challenged.
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Thus, when applied to clinical practice, the sepsis definitions do not con-
sistently categorise sepsis patients and, moreover, eliminate potential patients
due to the requirement of microbiological confirmation. The sepsis criteria define
clinical thresholds of abnormal ranges. However, they do not allow similar predic-
tion in sepsis diagnostics, as classification results in heterogeneous populations.
Thus, the usefulness of the definitions are undermined by the inability to stratify
patients by their baseline risk of mortality and by their response to therapy in
clinical care.
Alberti et al. [2002] suggested epidemiological studies have a ‘infection ap-
proach’ to focus on infection, which would provide a better understanding of
the associated conditions, risks, and outcomes of sepsis patients instead of a
‘sepsis approach’. In particular, clinical trials targeting the major sources of
infection (85% of reported sites are lung, abdomen, urinary tract, and blood-
stream [Alberti et al., 2002]) could reduce the heterogeneity of patients enrolled.
Furthermore, an editorial by Nasraway [1999] advocated the reduction of hetero-
geneity before initiating further experimental studies since heterogeneity results
in a low signal/noise ratio.
It should be noted, however, that both inter- and intra- patient variability in
physiological state, response to infection, and response to treatment all impact
patient outcome. Similarly, management also contributes to the heterogeneity of
sepsis classification and outcomes. In response to the high variability in critical
care patients, recent increases in the use of protocolized care aimed to reduce
the variability in outcome due to the variability in care. For example, the sep-
sis consensus definitions [Bone et al., 1992; Levy et al., 2003] aimed to provide a
standardisation of terminology for clinical trial entry criteria. However, the con-
sensus definitions do not stratify patients by their baseline risk of mortality and
by their potential to respond to therapy. In addition, the Surviving Sepsis Cam-
paign management guidelines [Dellinger et al., 2013] provide protocolized care
to reduce variability in sepsis care. And yet, the management guidelines have
reduced sepsis mortality [Levy et al., 2010], but sepsis mortality remains high.
Importantly, protocolized care alone has not been able to reduce variability in
patient outcomes. In particular, protocols do not address variability due to inter-
intra-patient variability in physiological state and response to disease, treatment,
and, therefore, outcome. This lack of patient-specificity defines the opportunity
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for patient-specific approaches to diagnosis, care, and patient management, which
are complementary to and fit within protocolized approaches.
Alternatively, patient-specific management approaches can be used to reduce
variability in outcome due to intra- and inter- patient variability in response to
therapy. This work will now introduce physiological model-based methods for
patient-specific solutions and will demonstrate the potential of these methods to
improve sepsis care. Future work in towards these solutions would determine if
this offers significant benefit.
2.4 Previous work
2.4.1 Glucose-insulin system model
A computational model of the metabolic glucose-insulin system offers the poten-
tial with clinical data to create patient-specific models that capture a patient’s
physiological status [Lin et al., 2011b]. This clinically validated model can track
patient-specific conditions and provide new means of diagnosis and opportuni-
ties for optimising therapy [Hann et al., 2005]. There already exist model-based
applications for the diagnosis of sepsis [Blakemore et al., 2008; Lin et al., 2011a].
A glucose insulin system model has been clinically validated in clinical tight
glycaemic control studies [Lin et al., 2011b; Fisk et al., 2012]:
˙BG = −pGBG(t)− SIBG(t)
Q(t)
1 + αGQ(t)
+
P (t) + EGPb − CNS
VG
(2.1)
Q˙ = nI(I(t)−Q(t))− nC
Q(t)
1 + αGQ(t)
(2.2)
I˙ = −nKI(t)−
nLI(t)
1 + αII(t)
− nI(I(t)−Q(t)) +
uex(t)
VI
+ (1− xL)
uen
VI
(2.3)
P˙1 = −d1P1 +D(t) (2.4)
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P˙2 = −min(d2P2, Pmax) + d1P1 (2.5)
P (t) = min(d2P2, Pmax) + PN(t) (2.6)
uen(t) = k1e
−I(t)k2/k3 (2.7)
where BG(t) is absolute blood glucose, I(t) is plasma insulin, and Q(t) is the
effect of previously infused insulin being utilized over time. EGPb is the con-
stant basal endogenous glucose production, which is suppressed with increasing
glucose concentrations. This suppression, independent of non-insulin mediated
glucose uptake by the central nervous system (CNS) is captured by the term pG.
In contrast, patient-specific insulin mediated glucose removal is captured with
insulin sensitivity, SI , which is identified (hourly) from clinical data as a time-
dependent variable that reflects evolving patient condition [Hann et al., 2005;
Lin et al., 2006; Blakemore et al., 2008; Lin et al., 2008; Chase et al., 2008]. Ex-
ogenous inputs are glucose appearance, P (t), from the carbohydrate content of
nutrition infusions via a two compartment model [Wong et al., 2006a], and in-
travenous insulin administration, uex(t). Other parameters are physiologically
defined population constants for insulin clearance rates (nI , nC , nK , nL), satu-
ration parameters (αG, αI), endogenous insulin secretion (uen), first-pass hepatic
removal (xL), or volumes (VG, VI) that have been validated over several studies.
The gastric absorption of glucose is defined for glucose in the stomach and gut
(P1, P2), transport rates between compartments (d1, d2), rates of glucose (Pmax,
P , D), and additional parenteral dextrose (PN). Finally, a generic representa-
tion of EGP when C-peptide data is unavailable is represented with base rates of
endogenous insulin production k1 and constants for exponential suppression (k2,
k3).
The essential parameter that drives the observed patient-specific glycemic
response to insulin and nutrition inputs is insulin sensitivity, SI . It is defined
by fitting the model to blood glucose measurements, and insulin and carbohy-
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drate administration inputs, from retrospective clinical data for each protocol
[Hann et al., 2005, 2008]. The resulting insulin sensitivity profile, SI(t), iden-
tifies a unique value every hour and the resulting profile thus varies hourly.
This model-based, insulin sensitivity metric and identification method have been
validated in glycaemic control protocol clinical trials in adults and neonates
[Chase et al., 2005a,b; Wong et al., 2006a,b; Le Compte et al., 2009; Fisk et al.,
2012] and SI has also shown good correlation to gold standard euglycemic clamp
data [Lotz et al., 2006, 2008]. Previous contributions of this author towards
developments of the glucose-insulin model and tight glycaemic control include
[Pretty et al., 2008; Razak et al., 2008; Chase et al., 2009a; LeCompte et al., 2009;
Chase et al., 2009b; Lin et al., 2010b,a; Chase et al., 2011; Lin et al., 2011b].
2.4.2 Model-based insulin sensitivity (SI) and sepsis
In intensive care, patient-specific metabolic model parameters have been used
as sepsis biomarkers because they can accurately reflect the inflammatory sta-
tus of the patient and severity of illness [Blakemore et al., 2008; Lin et al., 2011a;
Lotz et al., 2006; Langouche et al., 2007]. Sepsis has been observed with a reduc-
tion in insulin sensitivity [Agwunobi et al., 2000; Chambrier et al., 2000; Rusavy et al.,
2005; Chase et al., 2008]. There has also been a reported delay between endo-
toxin introduction and onset of decreased insulin sensitivity [Agwunobi et al.,
2000; Krogh-Madsen et al., 2004]. Moreover, the impact of drug choices on in-
sulin sensitivity [LeCompte et al., 2008] have been studied for glargine [Lin et al.,
2009b], corticosteroids [Pretty et al., 2009a], and glucocorticoids [Pretty et al.,
2009b, 2011].
The exact mechanisms remain unknown, but it has been suggested that sepsis
induces a strong counter regulatory hormone response and a strong inflammatory
immune response, both of which cause significant inflammation and a reduc-
tion in insulin sensitivity [Agwunobi et al., 2000; Virkama¨ki and Yki-Ja¨rvinen,
1994; Robinson et al., 2011; Dhar and Castillo, 2011; Marik and Raghavan, 2012;
Moreira and Alfenas, 2012]. More broadly, besides stress-induced hyperglycaemia,
studies have also examined the effects of body mass [Mica et al., 2014] and di-
abetes [Koh et al., 2012] on inflammation and sepsis. The relationship between
the metabolic and immune systems in inflammation and how they contribute to
sepsis pathology is being studied further, especially for developing metabolic and
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immune support for critically ill patients.
2.4.3 Analysis of Blakemore et al. [2008]
Blakemore et al. [2008] investigated the real-time diagnostic performance of model-
based SI to diagnose septic shock. Amongst an ICU study cohort of 30 sep-
sis patients, hourly model-based SI was calculated as well as sepsis categorised
hourly using the ACCP/SCCM definitions [Bone et al., 1992; Levy et al., 2003],
totalling 6,744 hours of sepsis and non-sepsis hours. An ROC curve was con-
structed within the sepsis cohort across all sepsis levels, yet primarily reported
at the diagnostic level of septic shock, the most severe form. Previously, this
work has been presented at the Engineering & Physical Sciences in Medicine and
Australian Biomedical Engineering Conference (EPSM ABEC 2008, Christchurch
NZ) [Parente et al., 2008].
Diagnostic performance results in Blakemore et al. [2008] were 78% sensitiv-
ity, 82% specificity, 2.8% PPV, and 99.8% NPV at an optimal cutoff value of
model-based SI = 8e-5 L/mU/min. The author’s analysis focused on predictive
values, concluding that low model-based SI does not make an effective septic
shock diagnostic, while high model-based SI rules out sepsis [Blakemore et al.,
2008]. However, it is important to note that predictive values alone do not ac-
curately reflect a diagnostic test’s performance, as predictive values are depen-
dent on disease prevalence overall [Smith et al., 2000] and in the data set used
to test the diagnostic. Therefore, further analysis in this thesis will now be con-
ducted using likelihood ratios (LHR), which are independent of disease prevalence
[Jaeschke et al., 1994a; Dujardin et al., 1994; Pauker and Kassirer, 1980] and are
an alternative to evaluating the predictive value of a test result.
Thus, further evaluation of Blakemore et al. [2008] showed that model-based
SI for a septic shock diagnosis resulted in 4.3 LHR+ and 0.27 LHR-. So, at the
optimal cutoff value, this was mid/low-level performance, specificially between
often providing useful information and rarely altering clinical decisions. Impor-
tantly, the majority of diagnostic cutoff values below and above the optimal
cutoff value are both at a performance level of often providing useful informa-
tion. Therefore, as opposed to the conclusion in Blakemore et al. [2008], in fact,
both low model-based SI and high model-based SI are useful for ruling in and
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ruling out septic shock, respectively.
However, a similar analysis of the diagnostic performance in terms of LHRs
for severe sepsis is low. At this level, all cutoff values rarely alter clinical deci-
sions. Yet, importantly, Blakemore et al. [2008] does show there is a real-time
diagnostic potential for model-based SI for ruling in and ruling out of septic
shock. Given this analysis, it is important to note which performance measures
and data reported would be useful for critical analysis. Specifically, a probability
density function should be provided of the model-based SI for the sepsis and
non-sepsis cohorts. In particular, this data would visualise the relative impact of
disease prevalence on the predictive values, as well as the discrimination between
cohorts. Result outputs should tabulate ranges of useful cutoff values, rather
than merely dichotomous positive/negative test outcomes at an optimal cutoff
value. Reporting cutoff value regions would be more helpful for a clinician to
infer the impact of a test result at a level of model-based SI output, as opposed
to a ‘positive’ or ‘negative’ test result. The area under the ROC curve (AUC)
should be provided for comparison to other diagnostic tests.
2.4.4 Analysis of Lin et al. [2011a]
Lin et al. [2011a] conducted a proof-of-concept study to evaluate the relationship
of model-based SI and sepsis, extending the work from Blakemore et al. [2008] by
utilising additional clinical measurements. The ICU study population consisted
of 36 sepsis patients totalling 9,208 hours of calculated model-based SI and physi-
ological data. The ACCP/SCCM definitions [Bone et al., 1992; Levy et al., 2003]
were used to categorise sepsis levels each hour, resulting in 226 sepsis hours and
8,982 non-sepsis hours. Two biomarkers were tested as sepsis diagnostics: 1)
model-based SI , and 2) a multivariate biomarker combining model-based SI with
temperature, heart rate, respiratory rate, blood pressure, and their respective
hourly rates of change. In particular, a recursive linear least squares method
was used to maximise discrimination of the multivariate biomarker. Finally,
ROC curves were constructed to evaluate the biomarker discriminative ability at
the diagnostic level of severe sepsis. Previously, this work has been presented
at the Modeling and Control in Biomedical Systems (MCBMS09) Symposium
[Lin et al., 2009a], which was then invited to be published in Computer Methods
and Programs in Biomedicine [Lin et al., 2011a].
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Lin et al. [2011a] reported the performance of model-based SI to diagnose
severe sepsis at 50% sensitivity, 76% specificity, 4.8% PPV, and 98.3% NPV,
yielding 2.1 LHR+ and 0.66 LHR-, at an optimal cutoff value of model-based
SI = 1.3e-4 L/mU/min. This level of performance rarely alters clinical decisions
across all cutoff values. When compared to the similar test in Blakemore et al.
[2008], this performance level is very similar.
Alternatively, for septic shock diagnosis, the optimal sensitivity in each study
differed greatly, with approximately 53% sensitivity in Lin et al. [2011a] as com-
pared to 78% sensitivity reported in Blakemore et al. [2008], while both had sim-
ilar specificities of around 85%. One possible source of this discrepancy could be
explained by the differences in the physiological models used by Blakemore et al.
[2008] [Wong et al., 2006b; Chase et al., 2005a] and Lin et al. [2011a] [Lonergan et al.,
2006; Chase et al., 2007; Lin et al., 2006].
The second developed diagnostic test, which used a multivariate biomarker,
showed improvement in performance compared to model-based SI alone. Opti-
mal severe sepsis diagnosis performed at 73% sensitivity, 80% specificity, 8.4%
PPV, and 99.2% NPV, yielding 3.65 LHR+ and 0.33 LHR-. These results are
on the border of rarely altering clinical decisions. Lin et al. [2011a] did evaluate
diagnostic performance in terms of predictive ability and acknowledged the in-
fluence of the low sepsis prevalence on predictive values in this data set, yet still
concluded that the multivariate biomarker provides a real-time negative predic-
tive diagnostic for severe sepsis. However, it is once again important to evaluate
diagnostic performance beyond predictive values, so it should be noted that the
majority of cutoff values below and above the optimal level do contribute to suf-
ficient LHR+ and LHR- performance that often provide useful information in
clinical decision making.
Thus, the work of Lin et al. [2011a] combined model-based SI with bed-
side clinical measurements from the ACCP/SCCM sepsis definitions [Bone et al.,
1992; Levy et al., 2003] to provide a significant improvement in the diagnosis of
severe sepsis as compared to model-based SI alone. Additionally, the use of clin-
ical predictors with model-based SI improved the diagnostic performance from
identifying septic shock to the less severe response to infection, namely severe
sepsis. However, it remains to be determined if including model-based SI to the
existing diagnostic clinical predictors makes a significant additional contribution
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to the diagnosis of severe sepsis.
Additionally, Lin et al. [2011a] provides a scatter plot (Poincare map) of the
observed hourly variation of sepsis categories and the associated multivariate
biomarker. This map is an initial look into the hourly transitions of sepsis cate-
gories and the multivariate biomarker, which could be extended into examining
sepsis time course and the inter- and intra- patient variation in the biomarker
to improve performance and add evolution over time to the diagnostic. It would
require further examination to evaluate the potential of real-time results to aid
in treatment and management of sepsis in the ICU.
2.5 Summary
Current sepsis diagnostics utilise combinations of microbiological, clinical, bio-
chemical, and immunological approaches, yet there remains a serious need for a
early and accurate sepsis diagnostic. Gold standard blood culture results return
only in retrospect and with significant 1–3 day delays. No biomarker studied has
performed with sufficient specificity or sensitivity for use in clinical practice. Fi-
nally, consensus sepsis definitions provide clinical thresholds of abnormal ranges,
but do not allow similar prediction and therefore, result in heterogenous cate-
gorisation. Thus, sepsis as a syndrome has proved difficult to diagnose or classify
at all, let alone rapidly or in real-time, due to high inter- and intra- patient
variability, which has not been addressed through uses of generalised protocol
care.
Alternatively, computational models of the glucose-insulin system together
with patient data can offer create patient-specific models. In particular, this
model has identified model-based insulin sensitivity (SI) as a patient-specific,
time-varying, real-time predictor of metabolic status which is related to patient
condition. Moreover, use of model-based SI has been shown to be a potential di-
agnostic for septic shock [Blakemore et al., 2008]. Combination of bedside clinical
predictors with model-based SI improved diagnostic for severe sepsis [Lin et al.,
2011a]. Further development of a multivariate clinical biomarker for use in real-
time patient-specific severe sepsis diagnostics will be continued in this work.
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2.6 Preface
There remains a serious need for an early, accurate, patient-specific diagnostic
test for severe sepsis to initiate life-saving treatment for the reduction of mor-
tality and improvement of patient treatment in critical care. In particular, a
statistical model of a biomarker may be more useful than generalised consensus
criteria by providing a probability-based approach. Also, independent evalua-
tion of the ACCP/SCCM sepsis definitions may be more useful than the strict,
hierarchical inclusion criteria to reduce ambiguous and heterogeneous classifica-
tion. Finally, a statistical model including time-dependency may be more useful
than retrospective microbiological confirmation to identify disease progression in
real-time. Therefore, the objectives of this work are to further develop the model-
based multivariate biomarker [Blakemore et al., 2008; Lin et al., 2011a] for severe
sepsis diagnosis by:
1. Examining the potential use of statistical models to develop a probability-
based diagnostic approach for clinical decision making.
2. Examining the classification outcome of the sepsis definitions scored inde-
pendently, rather than hierarchically.
3. Examining the potential use of statistical models to develop a time-dependent
diagnostic approach for clinical decision making.
This work addresses objective #1 in Chapter 3 with kernel density estimation
using a Bayes’ classifier to yield a posterior probability to support bedside clinical
decision making in real-time. This work addresses objective #2 in Chapter 4 with
independent classification criteria to reduce the impact of misclassification bias.
This work addresses objective #3 in Chapter 5 with a hidden Markov model
to link the hidden sepsis states to the observed patient data and to provide
time-dependency for real-time tracking of disease progression. Thus, this work
represents a proof-of-concept development of a novel, patient-specific, real-time
diagnostic to support bedside clinical decisions for sepsis.
Chapter 3
Kernel density estimates
3.1 Introduction
3.1.1 Clinical issues
Severe sepsis is a serious medical emergency defined as the combination of sys-
temic inflammatory response syndrome (SIRS) and organ failure due to infection
[Bone et al., 1992; Levy et al., 2003]. In the adult Intensive Care Unit (ICU),
severe sepsis has an 11–15% incidence, 30–60% mortality rate, $22,100 USD av-
erage cost per case, $16.7 billion USD annual total cost, and 1.5% projected
annual increase [Angus et al., 2001]. Sepsis is the 11th leading cause of all forms
of death in the USA [Murphy et al., 2013].
Early sepsis diagnosis allows early treatment, which is critical for patient
survival [Kumar et al., 2006]. However, blood culture test results to determine
if there is an infection return in 24–48 hours, while serious complications may
develop rapidly. Additionally, 50% of ‘culture negative’ sepsis cases are inconclu-
sive.
Sepsis is under-recognised and poorly understood due to confusion about its
definition, the lack of documentation of sepsis as a cause of death, inadequate
diagnostic tools, and inconsistent application of standardised clinical guidelines to
treat sepsis. Hence, rapid speed of diagnosis and the commencement of antibiotic
therapy are typically a function of clinical experience and intuition. The result
is more variable care and potential overuse of antibiotic therapy to mitigate risk.
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Thus, there remains a significant need for an objective, early, accurate, and
readily available diagnostic test for sepsis. Some biomarkers have been evalu-
ated for use in sepsis diagnostics. However, none have sufficient specificity nor
sensitivity to be routinely employed in clinical practice [Pierrakos et al., 2010].
In particular, hourly detection methods would provide the most rapid approach.
If effective, it would enable appropriate antibiotic dosing at the earliest oppor-
tunity, which has been shown to reduce mortality. Currently, no such accurate,
rapid, nor early diagnostic method exists.
3.1.2 Kernel density estimation
Kernel density estimation (KDE) can be used for classification and identification
of potential diagnostic biomarkers [Hastie et al., 2009; Moorhead et al., 2008]. As
an improvement over histograms, KDE provides smooth and continuous proba-
bility density functions of a random variable from a finite sample. These non-
parametric density estimates can be used for classification using Bayes’ theorem,
yielding a posterior probability [Hastie et al., 2009]. Thus, KDE provides a prob-
abilistic diagnostic approach given an objective metric associated with the disease
state.
Model-based insulin sensitivity (SI) provides a potential such metric, given
its relation to patient condition and objective calculation [Hann et al., 2005]. It
is used here in combination with other objective clinical metrics associated with
sepsis including: temperature, heart rate, respiratory rate, systolic blood pres-
sure, diastolic blood pressure, and the systemic inflammatory response syndrome
(SIRS) score. This research presents a kernel implementation of the Bayes classi-
fier by estimating the class conditional densities of severe sepsis and septic shock
cases and SIRS and sepsis controls and for classification.
Previously, the results of this project has been presented at the New Zealand
Post-Graduate Conference (NZPGC 2009, Wellington NZ) [Parente et al., 2009],
the Australia and New Zealand Industrial and Applied Mathematics (ANZIAM
2010, Queenstown NZ) [Parente et al., 2010e], the Trauma, Shock, Inflammation
and Sepsis (TSIS 2010, Munich DE) World Congress [Parente et al., 2010f,a], the
Health Research Society of Canterbury (HRSC 2010, Christchurch NZ) Clini-
cal Meeting [Parente et al., 2010d], the UK International Conference on Control
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(CONTROL 2010, Coventry UK) [Parente et al., 2010b], and the International
Sepsis Forum (Sepsis 2010, Paris FR) Symposia [Parente et al., 2010c].
3.1.3 Prior work
Model-based insulin sensitivity (SI) can be identified in real time [Chase et al.,
2007]. SI decreases with worsening condition [Chambrier et al., 2000] and in-
creases with improvement [Langouche et al., 2007; Evans et al., 2011]. Thus, high
SI correctly identifies 75% of patient hours with sepsis [Blakemore et al., 2008],
while SI and physiological data provides 73% sensitivity and 80% specificity for
severe sepsis [Lin et al., 2011a]. However, this approach more adequately rules
out sepsis, which is not the same as diagnostic, ruling in of the existence of sepsis.
3.1.4 Related work
Mica et al. [2012] used density estimates in a study to assess the diagnostic quality
of trauma scores for SIRS and sepsis in polytrauma patients. Importantly, density
estimates were not used for classification, but rather to describe the density mode
(peak) for each of: no SIRS, SIRS, and sepsis categories as a supplement to
other descriptive statistics. The main result showed APACHE II severity scores
[Knaus et al., 1985] distinguished no SIRS and sepsis with moderate accuracy
(0.82 (0.73–0.88) AUC), while all other trauma scores had low accuracy. However,
the clinically relevant question - discrimination between SIRS and sepsis - was not
reported. Upon visual inspection of the density estimates (Figure 1 [Mica et al.,
2012]), the densities overlap more with increasing SIRS severity, indicating that
APACHE II has low accuracy to discriminate between SIRS and sepsis.
Although SIRS criteria are included in the APACHE II score, the authors
acknowledge that the predictive quality should, in fact, be higher than 0.82 AUC
[Mica et al., 2012]. This outcome suggests that certain specific physiological pre-
dictors may improve diagnostic accuracy, thus providing greater clinical reso-
lution, as compared to SIRS and APACHE II bundled scores. Lastly, study
trauma scores were determined at admission (< 24 hours) into the Emergency
Department, which reflects immediate status, rather than real-time monitoring of
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changing patient condition. In contrast, the work presented in this research has
the advantage of resolution of physiological predictors and real-time classification.
Mart´ınez-Camblor [2011] explored the impact of classification errors on the
clinical decision making process and the effects on the final results on the variabil-
ity of the associated cutoff point estimator. To take into account the impact of
misclassification, the authors introduced a linear utility function, where a weight
determined the final impact between sensitivity and specificity, and then applied
the proposed methods on a data set to study the cutoff point of procalcitonin
(PCT) which correctly identified viral sepsis in the paediatric Intensive Care
Unit. Kernel density estimates were used for the logarithmic of the PCT levels
and for the utility function for PCT, which resulted in 0.88 sensitivity and 0.80
specificity, for an even weighting. As more weight was placed on sensitivity, the
obtained utility increased.
However, lacking repeatability, the authors did not provide a definition of
sepsis, population data, nor sample selection criteria, only the PCT minimum,
maximum, and quantile values for ‘positive’ and ‘negative’ groups. Moreover,
the PCT cutoff levels were not provided, which would be necessary for clinical
use and comparison to other PCT studies [Giamarellos-Bourboulis et al., 2004;
Uzzan et al., 2006; Tang et al., 2007; Nakamura et al., 2009]. It is important to
define the best cutoff levels with sufficient sensitivity and specificity to differen-
tiate a patient with sepsis form a patient without sepsis. Therefore, in this work,
90% sensitivity and specificity levels are reported with their associated posterior
probability cutoff values, as well as multilevel likelihood ratios (MLR) to return
more useful information beyond a dichotomised result to allow which levels of
test results yield clinically important information, and which levels of test results
do not.
3.2 Methods
3.2.1 Principle design
This case-control study compared the physiological symptoms of cases (severe
sepsis and septic shock) and controls (SIRS and sepsis) in real-time. 10048
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hours of sample data were obtained from the patient record of 36 adults in
the Christchurch Hospital ICU with confirmed sepsis and while on the SPRINT
glycemic control protocol. Additional data in the patient record included hourly:
model-based insulin sensitivity, temperature, heart rate, respiratory rate, systolic
blood pressure, diastolic blood pressure, and SIRS score. Use of this data was
approved by the NZ Upper South Islands Ethics Committee.
The ACCP/SCCM international sepsis definitions [Levy et al., 2003] were
applied to the patient record to categorise each data hour as SIRS, sepsis, severe
sepsis, or septic shock. Patient hours were removed if they had missing concur-
rent physiological data, model-based insulin sensitivity levels equalling zero, and
patient hours both without infection and less than two SIRS criteria. Thus, 6071
hours were available for developing the classifier.
Table 3.1: Table of hourly patient SIRS, sepsis, severe sepsis, and septic shock
[Levy et al., 2003].
categorisation SIRS sepsis severe sepsis septic shock
raw data 4918 (48.95%) 4888 (48.65%) 91 (0.91%) 151 (1.50%)
filtered data 1558 (25.66%) 4300 (70.83%) 85 (1.40%) 128 (2.11%)
Cohorts were defined at a discrimination level of severe sepsis. Therefore, in
this data set, samples comprised 213 hours of severe sepsis and septic shock cases
and 5858 hours of SIRS and sepsis controls (Table 3.1). Disease prevalence for the
dataset was therefore 3.5%, which is not atypical. Box and whisker plots of the
physiological data by sepsis score (Figure 3.1) show that some predictors may
be more useful in discriminating sepsis levels than others. Thus, the classifier
was designed to discriminate severe sepsis and septic shock from SIRS and sepsis
controls in real-time for sepsis patients using only their readily available bedside
monitored physiological data in the ICU.
3.2.2 Performance assessment
The following measures of diagnostic test accuracy are reported, as recommended
by Fischer et al. [2003]:
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Figure 3.1: Box and whisker plots of filtered predictor data (model-based insulin
sensitivity, temperature, heart rate, respiratory rate, systolic blood pressure, diastolic
blood pressure, and SIRS score) by sepsis level (SIRS, sepsis, severe sepsis, and septic
shock).
• Likelihood ratios (LHR)
• Multilevel likelihood ratios (MLR)
• Receiver operating characteristic (ROC) curve
• Area under the ROC curve (AUC)
• ROC cutoff yielding the highest discriminative ability
• Confidence intervals for each measure
Test performance with the potential to alter clinical decisions have likelihood
ratios with LHR+ above 10 and LHR- below 0.1, tests with 5–10 LHR+ and 0.1–
0.2 LHR- often provide useful information, while LHR+ below 3 and LHR- above
0.33 rarely alter clinical decisions [Jaeschke et al., 1994b]. Potentially useful tests
have a diagnostic odds ratio (DOR) well above 20 [Fischer et al., 2003]. Similarly,
perfect tests yield an AUC of 1.0. A test with an AUC greater than 0.9 has high
accuracy, while 0.7–0.9 AUC indicates moderate accuracy, 0.5–0.7 AUC is low
accuracy, and 0.5 AUC is a chance result [Swets, 1988].
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Additional measures of test accuracy include: sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV), and DOR. Sensitivity
and specificity levels over 90% are sufficient to be routinely employed in clini-
cal practice [Pierrakos et al., 2010], but are hard to obtain, if not impossible, to
achieve in sepsis diagnosis. Predictive values are mainly determined by the preva-
lence of infection [Smith et al., 2000]. Thus, predictive values alone depend not
only on the test’s properties, but also on the prevalence of disease in the popula-
tion. A very low incidence, as with severe sepsis, makes it very difficult to achieve
high PPV. Therefore, tests independent of disease prevalence are preferred and
employed, such as LHR, AUC, and DOR.
3.2.3 Technical exposition
Kernel density estimates were used for the development of joint probability den-
sity profiles for 213 hours of severe sepsis and septic shock cases and 5858 hours of
SIRS and sepsis controls and for classification. A kernel probability density profile
was made for each cohort and for the clinical predictor. Thus, a single density is
used to encompass the predictors. Finally, the unknown patient hour to be classi-
fied was tested against these established datasets, with the result being a classifi-
cation into either the case or control group. Optimal diagnostic performance from
the ROC curve was determined for resubstitution [Hastie et al., 2009], bootstrap
[Efron, 1983], and .632 bootstrap estimates [Efron and Tibshirani, 1997].
3.2.4 Kernel density estimates
3.2.4.1 Classification
The classification problem is generally defined as deciding to which class the
observed data belong. A classifier is a decision rule that assigns the data to a class
identity. Using a Bayes classifier, each observation is assigned to the class with the
largest posterior probability. Thus, for this sepsis binary classification problem,
there are two vectors (x) of observed data hours (M) of predictor dimensions
(d) from the cases (S: severe sepsis and septic shock) and control (N : SIRS and
sepsis) classes.
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Let x∗0 denote the values of the clinical predictors at the given patient hour,
and fˆS(x
∗
0) and fˆN (x
∗
0) denote the joint probability densities for cases and controls
at that value. For each hour, the posterior probability of being from the cases,
given the data values obtained at that hour is defined [Hastie et al., 2009]:
Pˆ r(S|x∗0) =
pˆiS fˆS(x
∗
0)
pˆiS fˆS(x∗0) + pˆiN fˆN (x
∗
0)
(3.1)
The posterior probability of being from the controls, given the data values ob-
tained at that hour is Pˆ r(N |x∗0) = 1− Pˆ r(S|x
∗
0).
In Equation 3.1, pˆiS and pˆiN are the prior probabilities of the sample being
in that group. The prior probabilities are usually set to the sample proportions
[Hastie et al., 2009] or to 0.5, if no reliable historical information is known or the
clinical judgement at that hour is a chance result. Thus, if the ratio in Equation
3.1 is greater than a specified probability threshold, then the sample is classified
as being from group S, otherwise it is classified as being from group N .
3.2.4.2 Kernel density estimation
Kernel density estimation is a non-parametric way to estimate the probability
density function of a random variable. The study data can be thought of as
samples of independently and identically distributed random variables, drawn
from a distribution with an unknown density. It is of interest to estimate the
shape of this function. A kernel implementation of the Bayes classifier estimates
the class conditional densities using kernel density estimators [Hastie et al., 2009].
As the study observation class identities are known, they can be used as a
training sample to construct a classifier. Thus, kernel density estimation is used
to estimate the joint densities fS and fN , which are the conditional probability
functions of x ∈ S given data on S and x ∈ N given data on N . The kernel
density estimator for fˆS is:
fˆS(x) = fˆ(x|S) =
1
MS
MS∑
i=1
φ(x; xS,i, HS) (3.2)
where MS is the total number of case hours, φ is a d-variate normal density with
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mean vector xS,i and d× d covariance matrix and bandwidth matrix HS ∈ R
d×d.
For example, if d = 2, this results in a contour plot of bivariate normal density
with non-zero diagonal covariance elements. In this study, d=7, which is the total
number of clinical predictors employed.
3.2.4.3 Practical considerations
The natural logarithm is used as a transform of positive components to use the
real components. The vector x is orthogonalized using the Cholesky or PCA
transform. To orthonormalize is essentially rotation and scaling of the observed
predictor vectors. Orthonormalization makes the covariance matrix for the or-
thonormalized x equal to the identity matrix, which provides matrix stability and
a fixed reference value.
3.2.4.4 Product kernel
Assuming a diagonal bandwidth matrix (Hi = diag(hi,1, ..., hi,d)), which presumes
variable independence, φ becomes:
φ(x; xi,j, Hi) =
d∏
ℓ=1
φ(xℓ; xi,j,ℓ, hi,ℓ)
where φ is univariate N(xi,j,ℓ, h
2
i,ℓ), which reduces the number of bandwidth com-
ponents needed to specify to d components. Thus, the kernel estimator for the
joint density or class conditional probability can be written as:
fˆS(x) =
1
MS
MS∑
i=1
(
d∏
ℓ=1
φ(xℓ; xS,j,ℓ, hS,i)) (3.3)
where the bandwidth hS,i = min{sS,i,
IQRS,i
1.348
}M
−1/(4+d)
S , sS,i is the sample stan-
dard deviation for the component, and IQR is the sample interquartile range for
the component. This approach results in a product of univariate kernels, and
thus the name, product kernel [Cooley and MacEachern, 1998].
The kernel product calculated in this way assumes mutual independence
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among the components of the rotated data. Alternatively, it can be said that the
kernel product assumes that the components of x are independent. The product
kernel does not assume this independence, but, instead, makes the weaker as-
sumption that the kernel has independent components. Practically, in this study,
these assumptions mean that it is assumed that the various clinical measurements
used as predictors are independent, even if all are associated with sepsis.
3.2.5 Resubstitution estimate
The resubstitution estimator of the classification error rate is obtained by using
the same sample to construct the classifier and also to assess its performance.
Hence, the resubstitution estimator underestimates the true error rate because
it has effectively been trained and tested on the same data. Resubstitution esti-
mates thus represent the maximum performance of the developed classifier.
3.2.6 Bootstrap estimate
Cross-validation is the traditional method to counteract the downward bias prob-
lem of the resubstitution estimator, which results in small bias, but high vari-
ability. To reduce the high variability of cross-validation, bootstrap estimators
were proposed by Efron [1983]. Bootstrap estimates using the stratified bootstrap
method randomly takes out 20% of the data to test against for each bootstrap
run and 1000 bootstrap runs were used to estimate the mean classification error
rate. Bootstrap estimates thus represent a measure of the minimum performance
of the developed classifier.
3.2.7 The .632 bootstrap estimate
Since each bootstrap sample of size n has only .632n different observations on
average [Efron, 1983], the bootstrap estimate tends to overestimate the true error
rate. Thus, Efron [1983] proposed the weight of .632 to mitigate this overesti-
mation. Thus, the .632 bootstrap estimate represents the overall performance of
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the developed classifier. It is effectively the bias corrected estimate between the
resubstitution and bootstrap estimates.
3.3 Results
3.3.1 Kernel density estimates
Product kernel estimates produced the greatest resubstitution AUC values (0.98–
0.99 AUC), which outperformed all kernel product estimates (0.81–0.85 AUC).
Prior probabilities using disease prevalence strongly skewed the distribution of
posterior probabilities, while 0.5 priors were not skewed and provided higher
AUCs for all error estimates. PCA transformations were unstable for bootstrap
estimates, while Cholesky transformations performed well. Thus, the following
results are from the most stable and accurate kernel density estimate, which used
the product kernel, 0.5 for the prior probabilities, and Cholesky transformation.
3.3.2 Resubstitution estimate
Table 3.2: Contingency table for resubstitution estimates
0.35 cutoff 213 cases 5858 controls predictive values
positive tests 201 352 PPV = 0.36
negative tests 12 5506 NPV = 1.00
performance measures sensitivity = 0.94 specificity = 0.94 AUC = 0.99
likelihood ratios LHR+ = 15.70 LHR- = 0.06 DOR = 262
At an optimal probability cutoff value of 0.35, the resubstitution estimate
yielded 94% sensitivity, 94% specificity, 0.99 AUC, 15.70 LHR+, 0.06 LHR-, 0.36
PPV, 1.00 NPV, and 262 DOR (Table 3.2). This level of AUC performance is
highly accurate [Swets, 1988], while the DOR shows this test is potentially useful
[Fischer et al., 2003]. Sensitivity and specificity perform at clinically significant
levels sufficient to be routinely employed in clinical practice [Pierrakos et al.,
2010]. Positive test results are obtained 15.7 times more often from a case hour
than a control hour, while negative test results are less than six-one-hundredths
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Figure 3.2: Subplot 1: ROC curve for the resubstitution estimate. Subplot 2: His-
togram of posterior probabilities normalised by cohorts. Subplot 3: Box and whisker
plot of posterior probabilities by sepsis score.
as likely to be found in a case hour than from a control hour. Thus, both LHRs
have the potential to alter clinical decisions [Jaeschke et al., 1994b]. However,
resubstitution yields the best estimate.
Figure 3.2 shows the ROC curve, a histogram of probabilities normalised by
cohorts, and a box and whisker plot of probabilities by sepsis score. The resub-
stitution estimate AUC is near perfect and performs with high accuracy [Swets,
1988]. Clinically significant levels of 90% sensitivity is reached at a cutoff value of
0.39 with 96% specificity. Similarly, 90% specificity is obtained at a cutoff value
of 0.29 with 96% sensitivity. LHR values at the optimal cutoff value are found
within the regions with the potential to change clinical decisions [Jaeschke et al.,
1994b].
The histogram in Figure 3.2 shows the optimal probability cutoff value and
90% performance cutoff values of each cohort, normalised by their respective
totals, which shows strong discrimination between cases and controls. The box
and whisker plot (Figure 3.2) shows that increasing illness severity does not alter
specificity (0.93 and 0.94) nor sensitivity (0.93 and 0.95). Thus, the resubstitution
estimate yields near perfect accuracy to discriminate between cases and controls
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independently of severity of illness.
Table 3.3: Resubstitution estimate LHR regions and MLRs
LHR+ 3 5 ≥ 10 LHR - ≤ 0.1 0.2 0.33
cutoff 0.13 0.2 0.3–1 cutoff 0–0.38 0.54 0.66
probability cases controls LHR+ probability cases controls LHR-
0.35–0.51 24 286 2.31 0.00–0.08 0 3282 0.00
0.51–0.67 37 62 16.41 0.08–0.17 0 1152 0.00
0.67–0.83 37 4 254.40 0.17–0.26 5 700 0.20
0.83–1.00 103 0 Inf 0.26–0.35 7 372 0.52
Table 3.3 shows LHR regions with the potential to alter clinical decisions
occur at cutoff values of 0.3 or greater for positive results and 0.38 and less for
negative results. Tests with cutoff values greater than 0.2 for positive results and
less than 0.54 for negative results often provide useful information. Finally, cutoff
values less than 0.13 for positive results and greater than 0.66 for negative results
rarely alter clinical decisions [Jaeschke et al., 1994b].
MLRs for the resubstitution estimate (Table 3.3) show that probability values
obtained above the optimal cutoff value often provide useful additional informa-
tion and have the potential to alter clinical decisions [Jaeschke et al., 1994b]. It
can be observed that the greater the probability, the greater the LHR+, such that
probability values obtained above a 0.51 probability threshold are very likely to
be from case hours. Alternatively, probability values obtained below the optimal
cutoff value often have the potential to alter clinical decisions [Jaeschke et al.,
1994b], where probability values obtained below a 0.26 probability threshold are
very likely to be from control hours. Thus, MLR values show useful information
for the positive identification of cases with greater accuracy with increasing prob-
abilities and for the correct identification of controls with greater accuracy with
decreasing probabilities.
3.3.3 Bootstrap estimate
At an optimal probability of 0.30, the bootstrap estimate achieved 69% sensitivity,
76% specificity, 0.78 AUC, 2.88 LHR+, 0.41 LHR-, 10% PPV, 99% NPV, and
7.04 DOR (Table 3.4). The classifier identifies the majority of both control and
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Table 3.4: Contingency table for bootstrap estimates
0.30 cutoff 43000 cases 1172000 controls predictive values
positive tests 29585 279637 PPV = 0.10
negative tests 13415 892363 NPV = 0.99
performance measures sensitivity = 0.69 specificity = 0.76 AUC = 0.78
likelihood ratios LHR+ = 2.88 LHR- = 0.41 DOR = 7.04
Figure 3.3: Subplot 1: ROC curve for bootstrap estimates. Subplot 2: Histogram of
probability normalised by cohorts. Subplot 3: Box and whisker plot of probability by
sepsis score.
case hours, but is not clinically significant [Pierrakos et al., 2010]. LHRs perform
at levels that rarely alter clinical decisions [Jaeschke et al., 1994b]. Although
the bootstrap estimate represents the minimum classifier performance, the AUC
shows moderate accuracy [Swets, 1988].
Figure 3.3 shows the ROC curve, a histogram of probability normalised by
cohorts, and a box and whisker plot of probability by sepsis score. The ROC curve
AUC shows moderate accuracy [Swets, 1988]. Clinically significant levels of 90%
sensitivity is reached at a cutoff value of 0.07 with 39% specificity. Similarly, 90%
specificity is obtained at a cutoff value of 0.53 with 50% sensitivity. LHR values
at the optimal cutoff value are in a clinically indiscriminate region.
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The histogram shows the optimal probability cutoff value and 90% perfor-
mance level cutoffs of each cohort, normalised by their respective totals, which
shows overlap between cases and controls. The box and whisker plot shows
that increasing illness severity among controls does not alter specificity (0.75 and
0.77). However, it changes sensitivity (0.63 and 0.73). Thus, the bootstrap esti-
mate yields a moderate test result with overlap between cases and controls that is
independent of severity of illness in controls, but is more accurate with increasing
severity of illness. However, it must also be noted that the bootstrap estimate is
the worst-case estimate.
Table 3.5: Bootstrap esimate LHR regions and MLRs
LHR+ 3 5 ≥ 10 LHR - ≤ 0.1 0.2 0.33
cutoff 0.32 0.53 1 cutoff - - 0.14–1
probability cases controls LHR+ probability cases controls LHR-
0.30–0.47 6536 134479 1.32 0.00–0.07 4134 460723 0.24
0.47–0.64 5444 69147 2.15 0.07–0.15 3961 197017 0.55
0.64–0.82 7301 39915 4.99 0.15–0.22 2571 126781 0.55
0.82–1.00 10304 36096 7.78 0.22–0.30 2749 107842 0.69
Table 3.5 shows LHR+ regions with the potential to alter clinical decisions
occur at a cutoff value of 1. Tests with cutoff values greater than 0.53 often pro-
vide useful information. Finally, cutoff values less than 0.32 rarely alter clinical
decisions for positive results [Jaeschke et al., 1994b]. LHR- regions do not per-
form in regions that contribute to clinical decision making, where cutoff values
greater than 0.14 for negative results rarely alter clinical decisions [Jaeschke et al.,
1994b].
MLRs for the bootstrap estimate (Table 3.5) show that positive results ob-
tained at probability values above 0.64 often provide useful additional information
[Jaeschke et al., 1994b] to identify cases. However, probability values obtained
below the optimal cutoff value rarely alter clinical decisions [Jaeschke et al.,
1994b]. MLRs for negative results at probability values below the optimal cutoff
value perform at values that rarely alter alter clinical decisions [Jaeschke et al.,
1994b]. Thus, MLR values for bootstrap estimates show even the worst-case
estimate often provides useful information for the positive identification of cases.
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Figure 3.4: ROC curve for .632 bootstrap estimates.
3.3.4 The .632 bootstrap estimate
Table 3.6: Contingency table for .632 bootstrap estimates
0.31 cutoff cases controls
performance measures sensitivity = 0.78 specificity = 0.83 AUC = 0.87
likelihood ratios LHR+ = 4.48 LHR- = 0.27 DOR = 16.83
At an optimal probability cutoff value of 0.31, the .632 bootstrap estimate
achieved 78% sensitivity , 83% specificity, 0.87 AUC, 4.48 LHR+, 0.27 LHR-,
and 16.83 DOR (Table 3.6). This optimal performance identifies the majority of
both case and control hours, yet neither sensitivity nor specificity reach the 90%
threshold to be clinically significant [Pierrakos et al., 2010]. LHR performance is
indeterminate, where both LHRs are outside of the range of rarely altering clinical
decisions, yet are not yet within the range of often providing useful information
[Jaeschke et al., 1994b].
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The ROC curve for the .632 bootstrap estimate (Figure 3.4) AUC shows
moderate accuracy [Swets, 1988]. The clinically significant level of 90% sensitivity
is reached at a cutoff value of 0.12 with 56% specificity. Similarly, 90% specificity
is obtained at a cutoff value of 0.44 with 67% sensitivity.
Table 3.7: .632 bootstrap estimate LHR regions
LHR+ 3 5 ≥ 10 LHR - ≤ 0.1 0.2 0.33
cutoff 0.22 0.34 0.56–1 cutoff - 0–0.17 0.39
Table 3.7 shows LHR+ regions with the potential to alter clinical decisions
occur at cutoff values greater than 0.56. Tests with cutoff values greater than 0.34
often provide useful information. Finally, cutoff values less than 0.22 rarely alter
clinical decisions for positive results [Jaeschke et al., 1994b]. LHR- regions do
not perform with the potential to alter clinical decisions. However, negative tests
with cutoff values less than 0.17 often provide useful information. Cutoff values
greater than 0.39 for negative results rarely alter clinical decisions [Jaeschke et al.,
1994b].
At the optimal cutoff value, the .632 bootstrap estimate performs at an inde-
terminate level, yet very near high accuracy, often providing useful information,
and clinical significance. Yet, overall, the .632 bootstrap estimate LHR regions
do perform within ranges of providing useful information and even potential to
alter clinical decisions for cases and controls. Thus, the overall performance of
the classifier is useful for clinical decision making for the identification of both
case and control hours in real time.
3.4 Discussion
3.4.1 Performance assessment
At the optimal cutoff values, the classifier correctly identifies 78% (69–94%) of
severe sepsis and septic shock hours and 83% (76–94%) of SIRS and sepsis hours.
However, to be routinely employed in clinical practice, sensitivity and specificity
should ideally perform at 90% to minimise false positives and false negatives
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[Pierrakos et al., 2010]. The resubstitution estimate performs at this clinically
significant level, as the posterior probability distributions (Figure 3.2) for both
cases and controls maintain tails for strong discrimination. For the bootstrap
estimate, the posterior probability distribution (Figure 3.3) maintains a tail for
controls. However, amongst case hours there is a more uniform distribution. The
variability observed amongst the cases brings down the minimum performance
and thus, the overall performance.
Amongst positive results obtained, 10–36% correctly identify severe sepsis
and septic shock hours, while 99–100% of negative results obtained correctly
identify SIRS and sepsis hours. However, these predictive values are influenced
by disease prevalence [Smith et al., 2000]. Thus, predictive values alone do not
represent the test’s inherent accuracy.
Alternatively, when a clinician needs to make inference about the presence
of absence of infection from an obtained test result, likelihood ratios can better
assess the predictive properties of a test, as they are independent of disease preva-
lence [Jaeschke et al., 1994a; Dujardin et al., 1994; Pauker and Kassirer, 1980].
At the optimal cutoff values LHR+ does not include one, rather a positive test
result is obtained approximately 4.5 times (2.9–15.7) more often from a patient
with severe sepsis or septic shock than from a patient with SIRS or sepsis. Sim-
ilarly, LHR- does not include 1, and the posterior probability of obtaining a
negative test result is less than twenty-seven-hundredths (six-one-hundredths to
forty-one-hundredths) as likely to be found in a patient with severe sepsis or sep-
tic shock than from a patient with SIRS or sepsis. Thus, overall, both LHRs
perform above the level of rarely altering clinical decisions, but do not yet per-
form within the levels that often provides useful additional information to guide
decision making [Jaeschke et al., 1994b]. The overlap of posterior probabilities
between cases and controls brings down the minimum performance and thus, the
overall performance.
LHRs and MLRs provide more important information beyond a dichotomised
negative or positive result and show which levels of test results yield clinically
important information and which levels do not [Jaeschke et al., 1994b]. For the
resubstitution estimate, the optimal cutoff value of 0.35 is sufficient as a test pos-
itive and test negative threshold (Table 3.3), as positive results obtained above a
cutoff value of 0.3 and negative results obtained below 0.38 both have the poten-
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tial to alter clinical decisions [Jaeschke et al., 1994b]. For the bootstrap estimate,
the optimal cutoff value of 0.30 represents the minimum cutoff value of clinical
utility for positive results (Table 3.5), yet is within a region of no clinical utility
for negative results. For the .632 bootstrap estimate (Table 3.7), the optimal
cutoff value of 0.31 represents the threshold for positive tests that provides useful
information in clinical decision making and the test negative minimum boundary
for clinical utility.
Interestingly, it can be observed that when the bootstrap estimate posterior
probabilities for cases has a more uniform distribution (Figure 3.3) as compared
to the resubstitution estimate, LHR- suffers, not LHR+. LHR+ is still useful for
clinical decision making because there remains a small overlap of posterior prob-
abilities at higher values. LHR- is less useful for clinical decision making because
of the greater overlap of cases and controls at lower posterior probability values.
Thus, for all estimates, positive test results provide useful identification of cases,
and the classifier is better at providing useful information for the identification of
cases than controls. This outcome suggests that between case and control hours
amongst sepsis patients, there remain physiological values useful to distinguish
control hours from becoming classified as case hours.
MLR results (Table 3.3 and Table 3.5) support the LHR findings, where pos-
itive results may provide useful information, with increasing utility at greater
probability values for positive results. Negative results may provide useful in-
formation, where lower probability values may be useful. Importantly, it can be
observed that this increasing accuracy is independent of severity of illness and
spectrum of disease (Figure 3.2 and Figure 3.3).
The 0.87 (0.78–0.99) AUC shows moderate to high accuracy [Swets, 1988]
and very good discriminative properties overall [Fischer et al., 2003]. Regions
of interest on the curve, particularly the 90% sensitivity and 90% specificity
regions of the ROC curve can be examined in Figures 3.2–3.4. In particular, at
90% sensitivity, specificity is 96% at a cutoff value of 0.39 for the resubstitution
estimate (Figure 3.2). Similarly, 90% specificity yields 96% sensitivity at a cutoff
value of 0.29. For the bootstrap estimate, 90% sensitivity is achieved with 39%
specificity at a cutoff value of 0.07, while 90% specificity with 50% sensitivity
occurs at a cutoff value of 0.53. Overall, 90% sensitivity is reached at 56%
specificity at a cutoff value of 0.12; 90% specificity and 67% sensitivity occur at a
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cutoff value of 0.44. These results show that other clinically acceptable tradeoffs
are possible in using this estimator.
The AUC is the single measure that summarises the discriminative ability
of a test across the full range of cutoffs, and which is independent of prevalence
[Fischer et al., 2003]. An AUC allows valuable statistical comparison of diagnos-
tic tests [Hanley et al., 1983; McNeil et al., 1983], particularly if applied to the
same patient population as to the same diagnostic question. Similarly, the diag-
nostic odds ratio (DOR) is an alternative way to compare tests. As potentially
useful tests have DOR over 20, this classifier performed with 16.83 (7.04–262)
DOR, and may be potentially useful towards its maximum performance.
3.4.2 Methodology
The final classifier used the product kernel, 0.5 prior probability, and Cholesky
transformation, rather than the kernel product, disease prevalence prior probabil-
ity, and PCA transformation. The kernel product assumes mutual independence
among the components of the rotated data. However, the product kernel does
not assume this independence, but the weaker assumption that the kernel has
independent components. Thus, the clinical predictors used cannot be assumed
to be mutually independent, which matches known physiological associations.
The prior probability in Equation 3.1 is essentially a scaling factor. With
the prior probability set to disease prevalence (pˆiS = 0.035 and pˆiN = 0.965),
the control term in Eq. 3.1 becomes so large that the optimal cutoff value is
unreasonably small. Therefore, prior probabilities were set at 0.5, thus cancelling
out in Eq. 3.1.
During bootstrap estimates with replacement, the Cholesky transformation
was observed to be more stable than the PCA transformation. Moreover, boot-
strap estimates without replacement resulted in higher AUC (0.78–0.79) than us-
ing replacement (0.76–0.77 AUC). Therefore, the Cholesky transformation with-
out replacement was used in the development of the classifier.
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3.4.3 Clinical significance
The classifier was designed to discriminate between severe sepsis and septic shock
cases and SIRS and sepsis controls in real-time from the bedside monitored phys-
iological data of adult sepsis patients in the ICU. The design presented used
controls that represent patient hours at risk of becoming a case. The controls
carry the same disease as cases, but of another severity, and are thus different
from the outcome of interest. However, because the difference between the cases
and the controls will be smaller than non-diseased controls, this choice results in
a lower statistical power to detect an exposure effect. Equivalently, this choice
also presents a much stricter, rigorous, and clinically realistic test of the classifier.
The classifier performance may be useful for clinical decision making in novel,
real-time, non-invasive monitoring at the ICU bedside amongst sepsis patients.
However, it is unknown how this test will perform with a broader spectrum of
alternative diagnoses. The classifier remains to be tested against patients with
non-infectious SIRS and shock. Though it should be noted that if the classi-
fier tests non-infectious SIRS and shock controls, the results would more likely
change specificity, rather than sensitivity. To better represent clinical reality, the
classifier should be tested against non-infectious SIRS and shock, which could
well lead to improved results than the conservative results presented.
Additionally, the classification model is time-independent. The joint proba-
bility density profiles (Equation 3.1) are developed from hourly concurrent phys-
iological data. However, both hourly physiological data and hourly sepsis states
are thus assumed to be independent from the previous hour with no influence from
the order in which they occur. Therefore, it may be useful to examine hourly
sepsis transition probabilities to improve estimation since sepsis is a disease with
a known evolution.
3.5 Summary
Severe sepsis is a medical emergency where fast and accurate diagnostic methods
remain to be developed in order to reduce patient mortality. A classifier was
designed to discriminate between 213 hours of severe sepsis and septic shock cases
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and 5858 hours of SIRS and sepsis controls in real-time for sepsis patients from
their bedside monitored physiological data in the ICU. Kernel density estimates
of the Bayes classifier were successfully implemented for the development of joint
probability density profiles for cases and controls and for classification.
The classifier performs with the greatest stability and accuracy when using
the product kernel, 0.5 prior probabilities, and Cholesky transformation. Diag-
nostic performance resulted in 0.78 (0.69–0.94) sensitivity, 0.83 (0.76–0.94) speci-
ficity, 0.87 (0.78–0.99) AUC, 0.10–0.36 PPV, 0.99–1.00 NPV, 4.48 (2.88–15.70)
LHR+, 0.27 (0.06–0.41) LHR-, and 16.83 (7.04–262) DOR. The classifier shows
good discriminative ability, often provides useful additional information for clini-
cal decision making, increased accuracy with greater posterior probabilities, and
independence from disease severity. Thus, the classifier can be readily assessed
at the bedside to yield a non-invasive and continuous estimate of sepsis state to
provide an accurate rule-in and rule-out measure and monitoring of interventions
in real time.
Possible design revisions include testing the classifier on a population includ-
ing a greater spectrum of alternative diagnoses, in particular non-infectious SIRS
and shock patients. The contribution of each clinical predictor to diagnostic ac-
curacy should be explored further, particularly SI . The variability observed in
the posterior probabilities during bootstrap estimation should be examined and
reduced, if possible, to improve overall diagnostic accuracy. Time dependence
should be introduced to the classification model to more represent the natural
course of sepsis and its sequelae.
Chapter 4
Misclassification Bias
4.1 Introduction
4.1.1 Clinical issues
Severe sepsis is a medical emergency where fast and accurate diagnostic methods
need to be developed to reduce patient mortality. In Chapter 3, a classifier was
designed to discriminate between 213 hours of severe sepsis and septic shock
cases, and 5858 hours of SIRS and sepsis controls in real-time using their bedside
monitored physiological data in the ICU. Kernel density estimates of the Bayes
classifier were successfully implemented for the development of joint probability
density profiles for cases and controls and for classification.
The classifier performed with the greatest stability and accuracy when using
the product kernel, 0.5 prior probabilities, and Cholesky transformation. Diag-
nostic performance resulted in 0.78 (0.69–0.94) sensitivity, 0.83 (0.76–0.94) speci-
ficity, 0.87 (0.78–0.99) AUC, 0.10–0.36 PPV, 0.99–1.00 NPV, 4.48 (2.88–15.70)
LHR+, 0.27 (0.06–0.41) LHR-, and 16.83 (7.04–262) DOR. The classifier showed
good discriminative ability, often provided useful additional information for clin-
ical decision making and, increased accuracy with greater posterior probabilities.
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4.1.2 Misclassification bias
Chapter 3 found some good results, but had limitations. The classifier remains to
be tested by a population with a large spectrum of alternative diagnoses, in par-
ticular, non-infectious SIRS and shock patients. The contribution of each clinical
predictor towards diagnostic accuracy should be explored, particularly SI . Vari-
ability observed in the distribution of posterior probabilities bootstrap estimate
should be reduced to improve the overall diagnostic accuracy. Finally, time de-
pendence should be introduced to the classification model to better represent the
natural course of sepsis and its sequelae.
Previously, this results of this project have been presented at the Australia-
New Zealand Intensive Care Society (ANZICS 2011, Taupo NZ) Annual Scientific
Meeting [Parente et al., 2011] and at the International Sepsis Forum (Sepsis 2013,
Rio de Janeiro BR) Symposium [Parente et al., 2013].
4.1.3 Prior work
An approach that could tackle the limitations of the previous work would be
to examine the performance of a continuous sepsis score, where patient clinical
signs independently contribute to the severity of disease, rather than hierarchi-
cally, as it is currently defined in the ACCP/SCCM definitions [Bone et al., 1992;
Levy et al., 2003]. The reason is that an independent definition can offer or make
assumptions that may better manage these limitations and improve sensitivity
and specificity by being more responsive to changing patient physiology in real-
time diagnostics.
Thus, this chapter presents an analysis of an independent sepsis definition for
sepsis detection. The same data is used as in Chapter 3. However, this research
seeks to better refine sensitivity, specificity and the other test metrics that assess
a good diagnostic.
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4.2 Methods
4.2.1 Principle design
Similar to Chapter 3, this chapter presents a classifier designed to discriminate
severe sepsis and septic shock cases from SIRS and sepsis controls. It seeks to
perform this task in real-time for sepsis patients using only their readily available
bedside monitored physiological data in the ICU. This case-control study differs
from the previous study by using a different, independent definition for sepsis.
The same study population is used as in Chapter 3 and seeks to better refine
sensitivity, specificity and the other test metrics that assess a good diagnostic.
Thus, this case-control study uses the same data as previously. However, it now
makes assumptions about the physiological symptoms of sepsis to utilise them
for real-time diagnosis.
The severity of the ACCP/SCCM sepsis definition increases conditionally
with concurrent SIRS score, Sequential Organ Failure Assessment score (SOFA),
and clinical intervention [Bone et al., 1992; Levy et al., 2003; Vincent et al., 1996].
However, hierarchical criteria fail to accurately classify sepsis when related phys-
iological manifestations are resolved, but the underlying infection remains. Thus,
to enable hour-to-hour sepsis classification, the diagnostic performance of a con-
tinuous sepsis score was examined. Therefore, patient-hours were categorised by
the ACCP/SCCM definitions [Bone et al., 1992; Levy et al., 2003], where each
category was scored independently, rather than hierarchically.
Table 4.1 illustrates the independent sepsis categorisation used in this study.
Notably, each of the sepsis categories: SIRS, sepsis, severe sepsis, and septic
shock, are independently scored and then summed. Moreover, adequate fluid re-
suscitation is defined across time for # hours and # hours for # mL fluids and #
fluids administered, respectively. The justification for this choice is acknowledg-
ing that fluids are administered over a time course and, once administered, are
considered sufficient for some time following for the total amount. Patient hours
were then removed if they had missing concurrent physiological data, model-based
insulin sensitivity levels equalling zero, and patient hours both without infection
and less than two SIRS criteria. Thus, 6550 hours were available for developing
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Table 4.1: Independent sepsis categorisation, where sepsis severities are scored and
summed (from Bone et al. [1992] and Levy et al. [2003]).
score category ranges
0 SIRS temperature > 38◦ C or < 36◦ C
heart rate > 90 beats per minute
respiratory rate > 20 breaths per minute
or PaCO2 < 32 mmHg
white blood cell count > 12000/cu mm or < 4000/cu mm
or > 10% immature (band) forms
+1 sepsis at least 2 SIRS criteria due to confirmed infection
+1 severe sepsis organ dysfunction
or hypoperfusion
or hypotension (systolic blood pressure < 90 mmHG)
+1 septic shock hypotension despite adequate fluid resuscitation
and perfusion abnormalities
the classifier.
Table 4.2: Table of hourly patient SIRS, sepsis, severe sepsis, and septic shock, inde-
pendently scored.
SIRS sepsis severe sepsis septic shock
1052 (16.1%) 3808 (58.1%) 1055 (16.1%) 635 (9.7%)
Cohorts were defined at a discrimination level of severe sepsis. Thus, this
categorisation defined 1052 hours of SIRS (level 0), 3808 hours of sepsis (level 1),
1055 hours of severe sepsis (level 2), and 635 hours of septic shock (level 3), shown
in Table 4.2. The disease prevalence was, therefore, 25.8% (1690 of 6550 hours).
Thus, the classifier was designed to discriminate independently categorised severe
sepsis and septic shock cases from SIRS and sepsis controls in real-time for sepsis
patients.
The limitation of the ACCP/SCCM sepsis definitions [Bone et al., 1992;
Levy et al., 2003] are illustrated in Figure 4.1. The criteria definitions are shown
in red, while the independent criteria used in this study are shown in green. It
can be observed that adherence to the criteria definitions leads to erratic hour-to-
hour sepsis categorisation. In particular, hourly jumps between sepsis and septic
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Figure 4.1: Sepsis score in time per patient. ACCMP/SCCM sepsis scores are in red
[Bone et al., 1992; Levy et al., 2003] and the independent criteria are in green.
shock are widely observed. The categorisation by the independently summed
criteria have resulted in more staged sepsis severity in time, as when hours of
fluid intervention plateaus in time. Notably, some SIRS and sepsis categorised
hours have been reevaluated to levels of severe sepsis and septic shock, suggest-
ing underlying SIRS symptoms may have been resolved, yet other more severe
indications of infection remain, such as organ failure and hypotension. However,
some patient sepsis categorisation in time remains unchanged.
Box and whisker plots of the physiological data by sepsis score (Figure 4.2)
show that some predictors may be more useful in discriminating sepsis levels than
others. It can be observed that the general trend of each physiological predic-
tor used for classification maintains the same trend as in the previous chapter.
However, some ranges and quantiles have been reduced by the independent cat-
egorisation. The classification does use the combination of all available bedside
physiological predictors from a data hour for training and/or testing the classi-
fier. Thus, the classifier will be trained and tested on a this new combination of
cohort data, where the model depends on the definitions of cases and controls.
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Figure 4.2: Box and whisker plots of patient data (model-based insulin sensitivity,
temperature, heart rate, respiratory rate, systolic blood pressure, diastolic blood pres-
sure, and SIRS score) by sepsis score.
4.2.2 Performance assessment
The following measures of diagnostic test accuracy are reported, as recommended
by Fischer et al. [2003]:
• Likelihood ratios (LHR)
• Multilevel likelihood ratios (MLR)
• Receiver operating characteristic (ROC) curve
• Area under the ROC curve (AUC)
• ROC cutoff yielding the highest discriminative ability
• Confidence intervals for each measure
Test performance with the potential to alter clinical decisions have likelihood
ratios with LHR+ above 10 and LHR- below 0.1, tests with 5–10 LHR+ and 0.1–
0.2 LHR- often provide useful information, while LHR+ below 3 and LHR- above
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0.33 rarely alter clinical decisions [Jaeschke et al., 1994b]. Potentially useful tests
have a diagnostic odds ratio (DOR) well above 20 [Fischer et al., 2003]. Similarly,
perfect tests yield an AUC of 1.0. A test with an AUC greater than 0.9 has high
accuracy, while 0.7–0.9 AUC indicates moderate accuracy, 0.5–0.7 AUC is low
accuracy, and 0.5 AUC is a chance result [Swets, 1988].
Additional measures of test accuracy include: sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV), and DOR. Sensitivity
and specificity levels over 90% are sufficient to be routinely employed in clini-
cal practice [Pierrakos et al., 2010], but are hard to obtain, if not impossible, to
achieve in sepsis diagnosis. Predictive values are mainly determined by the preva-
lence of infection [Smith et al., 2000]. Thus, predictive values alone depend not
only on the test’s properties, but also on the prevalence of disease in the popula-
tion. A very low incidence, as with severe sepsis, makes it very difficult to achieve
high PPV. Therefore, tests independent of disease prevalence are preferred and
employed, such as LHR, AUC, and DOR.
4.2.3 Technical exposition
Kernel density estimates were used for the development of joint probability den-
sity profiles for 1690 hours of severe sepsis and septic shock cases and 4860 hours of
SIRS and sepsis controls and for classification. A kernel probability density profile
was made for each cohort and for the clinical predictor. Thus, a single density is
used to encompass the predictors. Finally, the unknown patient hour to be classi-
fied was tested against these established datasets, with the result being a classifi-
cation into either the case or control group. Optimal diagnostic performance from
the ROC curve was determined for resubstitution [Hastie et al., 2009], bootstrap
[Efron, 1983], and .632 bootstrap estimates [Efron and Tibshirani, 1997].
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4.3 Results
4.3.1 Kernel density estimates
Classifiers were compared by their overall performance and stability. The high-
est AUC for resubstitution estimates were obtained with the product kernel (0.99
AUC), which outperformed the kernel product (0.81 AUC). PCA transformations
were unstable. Both selections of prior probabilities using the product kernel and
Cholesky transformation resulted in 0.88 AUC for bootstrap estimates. There-
fore, a prior probability of 0.5 was chosen as the scaling factor in to obtain a
more general optimal cutoff value. Hence, the following results presented are for
a classifier using the product kernel, prior probability of 0.5, and the Cholesky
transformation.
4.3.2 Resubstitution estimate
Table 4.3: Contingency table for resubstitution estimates
0.51 cutoff 1690 cases 4860 controls predictive values
positive tests 1594 255 PPV = 0.86
negative tests 96 4605 NPV = 0.98
performance measures sensitivity = 0.94 specificity = 0.95 AUC = 0.99
likelihood ratios LHR+ = 17.98 LHR- = 0.06 DOR = 300
The resubstitution estimate provided near perfect results. At an optimal cut-
off value of 0.51, the classifier performed with 94% sensitivity, 95% specificity,
86% PPV, 98% NPV, 17.98 LHR+, 0.06 LHR-, 0.99 AUC, and 300 DOR (Table
4.3). This sensitivity and specificity is sufficient for clinical use [Pierrakos et al.,
2010]. LHRs demonstrate the potential to change clinical decisions for both posi-
tive results and negative results [Jaeschke et al., 1994b]. The AUC has very high
accuracy [Swets, 1988]. The DOR demonstrates this test may be potentially use-
ful [Fischer et al., 2003]. However, this is the classifier’s maximum performance.
The ROC curve for the resubstitution estimate (Figure 4.3) not only demon-
strates the optimal cutoff value, but additional important regions useful for clin-
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Figure 4.3: Subplot 1: ROC curve for the resubstitution estimate. Subplot 2: His-
togram of posterior probabilities normalised by cohorts. Subplot 3: Box and whisker
plot of posterior probabilities by sepsis score.
ical decision making. The 0.99 AUC shows high accuracy [Swets, 1988]. 90%
sensitivity is achieved with 98% specificity at a posterior probability of 0.58,
while 90% specificity is found at 97% sensitivity with a posterior probability of
0.44. Thus, the optimal cutoff value of 0.51 performs with both sensitivity and
specificity sufficient for use in clinical care [Pierrakos et al., 2010].
This near perfect performance can be further visualised by observing the
small overlap in the distributions of the posterior probabilities normalised by
cohorts (Figure 4.3). Furthermore, the distribution of the posterior probabilities
by sepsis level shows 97% specificity for SIRS, 94% specificity for sepsis, 92%
sensitivity for severe sepsis, and 98% sensitivity for septic shock. Therefore, the
majority of regions on the ROC curve are useful for clinical decision making for
both cases and controls, independent of severity of illness.
The ability of the classifier to contribute to clinical inference and decision
making can be summarised by ranges of posterior probabilities providing impor-
tant information, as opposed to the dichotomised results due to an optimal cutoff
value. Table 4.4 shows that positive results obtained at posterior probabilities of
0.44–1 have the potential to change clinical decisions, where results above 0.32
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Table 4.4: Resubstitution estimate LHR regions and MLRs
LHR+ 3 5 ≥ 10 LHR - ≤ 0.1 0.2 0.33
cutoff 0.20 0.32 0.44–1 cutoff 0–0.57 0.67 0.76
probability cases controls LHR+ probability cases controls LHR-
0.51–0.63 168 187 2.58 0.00–0.12 0 2748 0.00
0.63–0.75 246 62 11.41 0.12–0.25 3 834 0.01
0.75–0.87 308 6 147.62 0.25–0.38 17 605 0.08
0.87–1.00 872 0 Inf 0.38–0.51 76 418 0.52
usually contribute useful information, and results below 0.20 rarely alter clinical
decisions [Jaeschke et al., 1994b]. Negative results obtained at posterior proba-
bilities of 0–0.57 have the potential to change clinical decisions, results below 0.67
usually contribute useful information, and results above 0.76 rarely alter clinical
decisions [Jaeschke et al., 1994b]. For values stratified around the optimal cutoff
value, MLR results (Table 4.4) show that positive results above 0.63 and negative
results below 0.38 have high predictive value. Therefore, the optimal probability
cutoff value is within the range of high predictive ability, which has the poten-
tial to change clinical decisions, while increasing values for positive results and
decreasing values for negative results improve accuracy.
4.3.3 Bootstrap estimate
Table 4.5: Contingency table for bootstrap estimates
0.48 cutoff 338000 cases 972000 controls predictive values
positive tests 273583 202993 PPV = 0.57
negative tests 64417 769007 NPV = 0.92
performance measures sensitivity = 0.81 specificity = 0.79 AUC = 0.88
likelihood ratios LHR+ = 3.88 LHR- = 0.24 DOR = 16.09
The bootstrap estimate performance is clinically indiscriminate. At an op-
timal posterior probability cutoff value of 0.48, the bootstrap estimate achieves
81% sensitivity, 79% specificity, 57% PPV, 92% NPV, 3.88 LHR+, 0.24 LHR-
, 0.88 AUC, and 16 DOR (Table 4.5). This sensitivity and specificity are not
sufficient for clinical use [Pierrakos et al., 2010]. The AUC shows moderate ac-
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Figure 4.4: Subplot 1: ROC curve for the bootstrap estimate. Subplot 2: Histogram
of posterior probabilities normalised by cohorts. Subplot 3: Box and whisker plot of
posterior probabilities by independently scored sepsis criteria (0: SIRS, 1: sepsis, 2:
severe sepsis, 3: septic shock).
curacy [Swets, 1988]. However both LHRs perform in an indiscriminate region
[Jaeschke et al., 1994b] and the DOR does not reach the level of being a poten-
tially useful test [Fischer et al., 2003]. However, this represents the classifier’s
worst potential performance.
The overall shape of the ROC curve for the bootstrap estimate (Figure 4.4)
shows moderate accuracy with 0.88 AUC [Swets, 1988]. Clinically significant
regions are reached, such as 90% sensitivity with 65% specificity at a posterior
probability cutoff value of 0.33. Similarly, 90% specificity is achieved with 64%
sensitivity at a posterior probability of 0.64. Moderate overlap was observed in
the distribution of posterior probabilities normalised by cohorts (Figure 4.4), thus
towards each tail, the optimal cutoff is reached earlier than the 90% performance
levels. Thus, the optimal performance does not reach clinical significance. The
distribution of posterior probabilities by sepsis class (Table 4.4) results in 86%
specificity for SIRS and 77% specificity for sepsis with 77% sensitivity for severe
sepsis and 87% sensitivity for septic shock. Thus, the optimal bootstrap estimate
performance does not reach clinical significance.
LHRs for the bootstrap estimate (Table 4.6) show that for positive results,
posterior probabilities obtained above 0.79 have potential of changing clinical
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Table 4.6: Bootstrap estimate LHR regions and MLRs
LHR+ 3 5 ≥ 10 LHR - ≤ 0.1 0.2 0.33
cutoff 0.39 0.57 0.79–1 cutoff 0–0.17 0.42 0.57
probability cases controls LHR+ probability cases controls LHR-
0.48–0.61 45677 90878 1.45 0.00–0.12 11202 394720 0.08
0.61–0.74 49838 54663 2.62 0.12–0.24 10796 145633 0.21
0.74–0.87 58695 30203 5.59 0.24–0.36 15803 121758 0.37
0.87–1.00 119373 27249 12.60 0.36–0.48 26616 106896 0.72
decisions, values above 0.57 often provide useful information, while values below
0.39 rarely alter clinical decisions [Jaeschke et al., 1994b]. For negative results,
posterior probabilities obtained below 0.17 have the potential of changing clinical
decisions, values below 0.42 often provide useful information, while values above
0.57 rarely later clinical decisions [Jaeschke et al., 1994b]. MLRs (Table 4.6) show
that for positive results, posterior probabilities obtained above 0.74 often provide
useful information, while values obtained above 0.87 have the potential to alter
clinical decisions. For negative results, posterior probabilities obtained below
0.24 have the potential to alter clinical decisions, while values obtained below
0.12 have the potential to alter clinical decisions. Thus, there is a window of
cutoff values (0.43–0.56) which lead to indiscriminate results for clinical decision
making, otherwise the bootstrap estimate may provide useful information.
4.3.4 The .632 bootstrap estimate
Table 4.7: Contingency table for .632 bootstrap estimate
0.49 cutoff cases controls predictive values
performance measures sensitivity = 0.86 specificity = 0.85 AUC = 0.92
likelihood ratios LHR+ = 5.70 LHR- = 0.17 DOR = 33.56
The .632 bootstrap estimate describes the overall classifier performance. At
an optimal posterior probability cutoff value of 0.49, the classifier reaches 86%
sensitivity, 85% specificity, 5.70 LHR+, 0.17 LHR-, 0.92 AUC, and 34 DOR
(Table 4.7). This level of optimal performance does not reach the 90% threshold of
neither sensitivity nor specificity for clinical use [Pierrakos et al., 2010]. However,
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Figure 4.5: ROC curve for the .632 bootstrap estimate.
the LHRs often provide useful information for both positive and negative results
[Jaeschke et al., 1994b]. Furthermore, the AUC shows high accuracy [Swets, 1988]
and the DOR shows this is a potentially useful test [Fischer et al., 2003].
The .632 bootstrap ROC curve (Figure 4.5) demonstrates the 0.92 AUC, op-
timal cutoff value, 90% sensitivity and specificity regions, and LHR regions. At
90% sensitivity, the classifier obtains 79% specificity at a posterior probability
value of 0.41. At 90% specificity, the classifier obtains 79% sensitivity at a pos-
terior probability value of 0.57. It can be observed that the majority of the ROC
curve is within either 90% sensitivity or 90% specificity region. Thus, positive
results obtained above 0.41 and negative results obtained below 0.57 are clinically
significant.
Table 4.8: .632 bootstrap estimate of LHR regions
LHR+ 3 5 ≥ 10 LHR - ≤ 0.1 0.2 0.33
cutoff 0.31 0.46 0.63–1 cutoff 0–0.35 0.52 0.66
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The LHR regions for the .632 bootstrap estimate (Table 4.8) show that for
positive results, posterior probabilities above 0.63 have the potential to change
clinical decisions, values above 0.46 often provide useful information, and values
below 0.31 rarely alter clinical decisions. For negative results, posterior proba-
bilities below 0.35 have the potential to change clinical decisions, values below
0.52 often provide useful information, and values above 0.66 rarely alter clinical
decisions. Thus, the classifier performs within the 90% regions for negative re-
sults (0–0.57) and positive results (0.41–1), and while outside of the 90% regions
(0.41–0.57), the classifier still often provides useful information for both positive
results and negative results. Therefore, the overall performance of the classifier
often provides useful information and the potential to change clinical decisions.
4.4 Discussion
4.4.1 Performance assessment
The classifier correctly identifies 86% (81–94%) of severe sepsis and septic shock
hours, 85% (79–95%) of the SIRS and sepsis hours. Positive results are 6 (4–18)
times more likely to come from a case than a control, while negative results are
less than seventeen-hundredths (six-one-hundredth to twenty-four-hundredths) as
likely to be found in a case than a control hour. The classifier has high accuracy
(0.92; 0.88–0.99 AUC) and is a potentially useful test (34; 16–300 DOR).
The histogram of the posterior probabilities for the best performing resubsti-
tution estimate (Figure 4.3) demonstrated strong discrimination between cases
and controls, such that the optimal cutoff value is found within clinically signifi-
cant regions. For the classifier’s minimum performance in the bootstrap estimate
(Figure 4.4), each cohort maintains tail regions, however the optimal performance
value is not yet clinically significant. Yet, notably, these results are an improve-
ment over the previous chapter’s result, where the posterior probability of cases
had a uniform distribution.
Moreover, it can be observed in the box and whisker plot for the bootstrap es-
timate (Figure 4.4) that there is more discrimination between cases and controls,
particularly between sepsis and severe sepsis. Thus, these results suggest that this
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methodology of further refining the assumptions of case definitions contribute to
the greater discriminative ability of the classifier and clinical significance.
4.4.2 Methodology
Kernel density estimates were again employed successfully to provide a continuous
estimate of the posterior probability of sepsis at a given data hour. The alterna-
tive design of this study employed an independent classification of sepsis severity
levels (Table 4.1), where characteristics of SIRS, sepsis, severe sepsis, and septic
shock were identified and summed, as opposed to the hierarchical ACCP/SCCM
criteria [Bone et al., 1992; Levy et al., 2003]. It was observed that application of
the independent sepsis criteria capture the a more staged and clinically observed
evolution of sepsis over time, including plateaus of septic shock during adminis-
tration of intravenous fluid resuscitation (Figure 4.1). Hence, it is a better metric,
especially for real-time hour-to-hour monitoring.
The evaluation of a test’s accuracy is contingent on a gold standard criterion
that discriminates a cohort into cases and controls. However, the reality of gold
standard diagnostics in sepsis requires alternative methods of classification. The
positive blood culture does not meet the needs of modern sepsis diagnostics, as
results yield high rates of both false positive and false negative results. As a
consequence, the clinical gold standard uses both positive blood culture results
and clinical signs of infection as an effective gold standard.
In research, this approach may force data samples to be omitted, which may
be classified ambiguously from the analysis [Ku¨ster et al., 1998]. These omissions
prevent the problem of misclassification bias. However, such analysis then intro-
duces the alternative problem of case-control bias, which has been identified as
the most important source of bias for overestimating test accuracy [Lijmer et al.,
1999]. Most clinicians are able to distinguish between a severely ill patient with
suspected sepsis and a healthy control hospitalised in the same unit without any
additional testing. However, clinicians seek help from testing exactly for the
ambiguous cases, which are omitted in the analysis approach described above.
Despite decades of research, no suitable solution has been offered for this prob-
lem, which in turn means the gold standard is not necessarily perfect.
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4.4.3 Clinical significance
The classifier’s optimal .632 bootstrap estimated sensitivity and specificity is not
sufficient for use in clinical care [Pierrakos et al., 2010]. However, there remain
performance measures - besides the optimal performance levels - indicating clin-
ical significance. For example, 90% of severe sepsis and septic shock cases are
found within a posterior probability range of 0.41–1 and 90% of SIRS and sepsis
cases are in a posterior probability range of 0–0.57 (Figure 4.5). However, in a
clinical setting, physicians do not know whether infection is present or absent
when tests are ordered. Physicians need to make inferences about the presence
or absence of infection from an obtained test result (Table 4.3 and Table 4.5).
Importantly, this inference can be quantified using LHRs.
LHRs for positive results from 0.63–1.00 have the potential to change clinical
decisions, 0.46 and above often provide useful information, and results below 0.31
rarely alter clinical decisions [Jaeschke et al., 1994b]. LHRs for negative results
from 0–0.35 have the potential to change clinical decisions, 0.52 and below often
provide useful information, and results above 0.66 rarely alter clinical decisions
[Jaeschke et al., 1994b]. It is equally important to distinguish sensitivity and
specificity, which describe a proportion of a cohort, while LHRs compare the
overlap of positive and negative results at a particular posterior probability value.
Thus, examination of these results suggests that clinical significance relies more on
making inference from a test result, informed by the LHRs, rather than sensitivity
and specificity.
As a result, the overall performance of the classifier has clinical significance
for positive results, and provides useful information and the potential to change
clinical decisions for positive results obtained at a posterior probability of 0.46–1.
Negative results obtained at a posterior probability of 0–0.52 also provide useful
information and the potential to change clinical decisions. Thus, any selection of
diagnostic cutoff value to obtain 90% sensitivity, 90% specificity, and clinically
significant LHRs are available throughout the entire ROC curve of the classifier.
Therefore, the majority of results from the ROC curve are, in fact, clinically
significant.
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4.4.4 Limitations and Next Steps
To this point, this research has developed a classifier for the real-time identifi-
cation of sepsis. The classifier performs with the greatest accuracy and stability
using the product kernel and Cholesky transformation. Concerning the selec-
tion of prior probabilities, the bootstrap estimate results in this chapter had
equal performance. Thus, it would be useful to explore Bayesian calculations
to integrate an individual test result (posterior probability) with the clinician’s
judgement about the probability of infection in the patient under investigation
(prior probability).
This research also explored an independent sepsis categorisation that was
not hierarchical, to identify the cases in this case control study. This design
decision indicates the inherent trade-off between misclassification bias and case
control bias in a studies without a reliable gold standard. Future implementation
goals for sepsis diagnostics should focus on both accurate and real-time sepsis
classification.
4.5 Summary
Sepsis score classifications increase conditionally with concurrent SIRS score,
SOFA score, and clinical intervention. However, hierarchical criteria fail to accu-
rately classify sepsis when related physiological manifestations are resolved, while
the underlying infection remains. To enable hour-to-hour sepsis classification, this
research examined the diagnostic performance of a continuous sepsis score that
was not hierarchical and thus provided a smoother, more realistic time-varying
signal for classification.
A severe sepsis biomarker was developed from model-based insulin sensitivity,
temperature, heart rate, respiratory rate, blood pressures, and SIRS score from
36 adult sepsis patients from the Christchurch Hospital ICU. SIRS, sepsis, severe
sepsis, and septic shock patient hours were categorised by the ACCP/SCCM
guidelines, where each category was scored independently, rather than hierarchi-
cally. Kernel density estimates were used to classify 1690 hours of severe sepsis
and septic shock cases and 4860 hours of SIRS and sepsis controls. Optimal di-
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agnostic performance from the receiver operating characteristic (ROC) curve was
determined for resubstitution, bootstrap, and .632 bootstrap estimates.
Using the .632 bootstrap estimate, the severe sepsis biomarker achieved 86%
(81–94%) sensitivity, 85% (79–95%) specificity, 0.92 (0.88–0.99) AUC, 6 (4–18)
LHR+, 0.17 (0.06–0.24) LHR-, 57–86%) PPV, 92–98%) NPV, and 34 (16–300)
DOR at an optimal posterior probability cutoff value of 0.49. This clinical
biomarker can thus be readily assessed at the bedside to yield a non-invasive
and continuous estimate of the probability of severe sepsis. The results show
high accuracy as a potential severe sepsis diagnostic and monitoring response to
sepsis interventions in real time.
Chapter 5
Hidden Markov Model
5.1 Introduction
5.1.1 Clinical issues and prior work
Severe sepsis in the ICU presents a medical emergency where effective monitor-
ing and early diagnostic approaches remain to be developed to reduce patient
mortality. In the previous chapter, an independent sepsis criteria was employed
to label 1690 severe sepsis and septic shock case hours and 4860 hours of SIRS
and sepsis control hours. Kernel density estimates of the Bayes classifier were
successfully implemented for the development of joint probability density profiles
for cases and controls and for classification using real-time bedside monitored
physiological data in the ICU.
The classifier performed with the greatest stability and accuracy when using
the product kernel, 0.5 prior probabilities, and Cholesky transformation. Diag-
nostic performance resulted in 86% (81–94%) sensitivity, 85% (79–95%) speci-
ficity, 0.92 (0.88–0.99) AUC, 6 (4–18) LHR+, 0.17 (0.06–0.24) LHR-, 57–86%
PPV, 92–98% NPV, and 34 (16–300) DOR at an optimal posterior probabil-
ity cutoff value of 0.49. Thus, the classifier showed high discriminative ability,
provided additional information for clinical decision making at the majority of
posterior probability cutoff values, and improved classification over the hierarchi-
cal ACCP/SCCM sepsis criteria [Bone et al., 1992; Levy et al., 2003].
The independent criteria used to categorise cases and controls for training and
testing the classifier improved the diagnostic accuracy from the given hierarchical
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criteria. In particular, the posterior probabilities were more greatly discriminated
between cases and controls and each distribution had tailed ends. However, no
time dependency was introduced in the classification model that would represent
the natural course of sepsis and its sequelae. This added data is available and
could improve accuracy.
5.1.2 Hidden Markov model
This chapter continues to use real-time monitored physiological measurements,
which are regarded to be the most useful for indicating the patient sepsis state.
Yet, it will use an alternative mathematical model to link the data to the state
of sepsis. This chapter considers the hidden Markov model (HMM) because of
its ability to model hidden or unobservable states of a system, in this case, the
sepsis state as well as its ability to include time dependency. For this purpose, a
HMM is developed and is described how inference can be performed in this case.
To be useful, the resulting model is computationally tractable and interpretable
by health care professionals.
5.1.3 Related work
Lee et al. [2006] described HMMs for tracking the health of premature babies.
Much of the method section in this chapter is from the introduction to HMMs
provided by Lee et al. [2006] as the goal is to try a proven approach in a new
diagnostic area. For a detailed account, see Cappe´ et al. [2005].
Rangel-Frausto et al. [1998] used a Markov model to report the transition
probabilities for each sepsis state. The authors used the model to define the
theoretical reduction in morbidity and mortality with antisepsis agents at treat-
ment at all sepsis stages [Rangel-Frausto et al., 1998]. However, this work did
not include the physiological observations which are used for sepsis diagnostics
in a clinical setting.
Gultepe et al. [2014] developed an automated decision support system to
identify patients at high risk for hyperlactatemia based upon routinely measured
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vital signs and laboratory findings. A HMM was applied, amongst other mod-
els, to the time series data of temperature, white blood count, respiratory rate,
and mean arterial pressure to predict high or low serum lactate levels in a co-
hort of patients meeting SIRS criteria admitted to a large tertiary care hospital
[Gultepe et al., 2014]. Thus, serum lactate levels were used as a biomarker for
end-organ hypoperfusion, impending shock, and increased risk of death in sep-
sis [Bakker et al., 1996; Nguyen et al., 2004]. Rather, the work presented in this
chapter utilise the clinical presentations defining sepsis as an evaluation of the
consensus conference definitions, to allow us to decide if these are well chosen or
not.
Brause [2002] aimed to provide probability-based diagnosis of the individual
case history. The author used a HMM to learn the underlying sepsis state tran-
sition probabilities to predict the probability of sepsis. The highest performing
HMM developed performed with 91.1% sensitivity with 83.1% specificity for the
38 deceased and 32 dismissed patient outcomes in cases of abdominal septic shock,
respectively. This model used the three most recorded variables in the patient
records, but did not report which ones. Thus, the author concludes that using
HMMs is a good tool for extracting knowledge from patient symptom time series,
but extends much farther into limitations and future work to be done. Thus, it
is clear that HMMs for sepsis diagnosis is quite understudied, and presents a new
opportunity.
5.2 Methods
5.2.1 Principle design
This chapter presents a mathematical model to link the monitored physiology of
the same sepsis patient population to sepsis state. The physiological variables
regarded to be most useful for detecting sepsis are SIRS and organ dysfunction
measures (see Table 1.2). The same study population is used as in Chapter 3 and
Chapter 4, yet now includes the evolution of sepsis states and state transitions in
time. Readily available bedside measurements used to develop the model include:
temperature, heart rate, respiratory rate, systolic blood pressure, diastolic blood
pressure, and SIRS score [Bone et al., 1992; Levy et al., 2003]. The additional
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measurement of model-based insulin sensitivity is used as an objective metric
associated with disease state [Hann et al., 2005]. These observations depend on
the of the underlying, unobserved sepsis state that is being modelled.
5.2.2 Performance assessment
The following measures of diagnostic test accuracy are reported, as recommended
by Fischer et al. [2003]:
• Likelihood ratios (LHR)
• Multilevel likelihood ratios (MLR)
• Receiver operating characteristic (ROC) curve
• Area under the ROC curve (AUC)
• ROC cutoff yielding the highest discriminative ability
• Confidence intervals for each measure
Test performance with the potential to alter clinical decisions have likelihood
ratios with LHR+ above 10 and LHR- below 0.1, tests with 5–10 LHR+ and 0.1–
0.2 LHR- often provide useful information, while LHR+ below 3 and LHR- above
0.33 rarely alter clinical decisions [Jaeschke et al., 1994b]. Potentially useful tests
have a diagnostic odds ratio (DOR) well above 20 [Fischer et al., 2003]. Similarly,
perfect tests yield an AUC of 1.0. A test with an AUC greater than 0.9 has high
accuracy, while 0.7–0.9 AUC indicates moderate accuracy, 0.5–0.7 AUC is low
accuracy, and 0.5 AUC is a chance result [Swets, 1988].
Additional measures of test accuracy include: sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV), and DOR. Sensitivity
and specificity levels over 90% are sufficient to be routinely employed in clini-
cal practice [Pierrakos et al., 2010], but are hard to obtain, if not impossible to
achieve in sepsis diagnosis.
Predictive values are mainly determined by the prevalence of infection [Smith et al.,
2000]. Thus, predictive values alone depend not only on the test’s properties, but
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also on the prevalence of disease in the population. A very low incidence, as with
severe sepsis, makes it very difficult to achieve high PPV. Therefore, tests inde-
pendent of disease prevalence are preferred and employed, such as LHR, AUC,
and DOR.
5.2.3 Technical exposition
A hidden Markov model was used to link observed measurements to unobserved
sepsis states. A HMM topology was defined to represent the study variable rela-
tionships, given the observed time series of physiological variables. In particular,
the topology defines transitions for the hidden states and the distributions of the
observations conditioned on each hidden state. The independent sepsis criteria in
Chapter 4 was used for hourly sepsis categorisation. Thus, the labelled data can
be used to estimate the transition probabilities of the hidden sepsis states. The
conditional distributions, P (observation|sepsis state), were found using the joint
probability densities using kernel density estimates as in Chapter 3. Finally, the
hidden states are estimated by determining the most probable path of the joint
probability of the observed sequence and the hidden sequence. Upon determining
the posterior probability of a patient sepsis state, the patient hour is compared
against the established dataset and diagnostic performance from the ROC curve
was determined for resubstitution, repeated holdout estimate, and leave one out
estimate.
5.2.4 Hidden Markov model
This section describes the HMM used for tracking sepsis state and discusses how
inference proceeds for the model. A short introduction to the HMM is provided
from Lee et al. [2006], with details in Cappe´ et al. [2005].
A HMM has two sets: one set of observed states, X, and another set of hidden
(unobserved) states, Y, containing K elements. The time series observations,
x1, ..., xT , are members ofX. The probability distribution of any one observation,
xt, depends only on the hidden state at time t, yt ∈ Y. This dependency means
that given yt, xt is conditionally independent of the other observations, which
68 CHAPTER 5 HIDDEN MARKOV MODEL
is depicted schematically in Table 5.1. Meanwhile, the hidden states, y1, ..., yT ,
evolve according to a Markov chain with a K ×K transition matrix, Q(i, j) =
P (yt = j|yt−1 = i), which contains the probabilities of transitions between all the
pairs of members in Y.
Table 5.1: Hidden Markov model
xt−1 xt xt+1
↑ ↑ ↑
→ yt−1 → yt → yt+1 → →
A topology of the HMM represents the Markov chain for the hidden states
graphically, showing the members of Y and their transition probabilities. Com-
plete specification of a HMM requires the definition of its topology, the transition
matrix, Q, for the hidden states, and the distributions of the observations con-
ditioned on each hidden state.
The HMM considered in this research is a model with two hidden states:
healthy and ill (labelled as 1 and 0, respectively). So, in this case Y = {y1, y2} =
{0, 1}. When the hidden state is 0, the observations have the distribution P (xt|yt =
0), and when the hidden state is 1, the observations have distribution P (xt|yt =
1). This HMM is depicted in Table 5.2.
Table 5.2: Hidden Markov model with two hidden states
P (x|y = 0) P (x|y = 1)
↑ Q(0,1) ↑
Q(0,0)  0 ⇄ 1  Q(1,1)
Q(1,0)
With this chosen model topology, the HMM is trained by using the labelled
data to estimate the transition probabilities in Q and the conditional distribu-
tions, P (xt|yt = k) for k = 1, ..., K. After training, the model is ready to be used
to estimate the hidden states from input data. For both cases and controls, the
relevant transition probabilities and conditional distributions can be estimated,
given the hidden state. The hidden states are known from the labelled data used.
Thus, the transition probabilities can be estimated by:
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Qˆ(i, j) =
number from state i to state j
number from state i to any state
(5.1)
5.2.5 Estimating the hidden states
Let Xt = {x1, ..., xt} and St = {S1, ..., St} be vectors of per patient data observed
until now (time = t). To then determine the probability of sepsis given these
observations:
P (St|Xt) ∝
∑
S1,...,St−1
P (Xt|St)P (St|St−1)P (St−1,Xt−1)
= P (Xt|St)
∑
St−1
[P (St|St−1)
∑
S1,...,St−1
P (St−1,Xt−1)]
= P (Xt|St)
∑
St−1
P (St|St−1)P (St−1,Xt−1)
(5.2)
The term P (St−1,Xt−1) =
P (St−1|Xt−1)
P (Xt−1)
, where the proportionality constant is ig-
nored in the denominator. Thus,
P (St|Xt) ∝ P (Xt|St)
∑
St−1
P (St|St−1)P (St−1|Xt−1) (5.3)
Therefore, the estimates for sepsis cases and controls are:
P˜ (St = 1|Xt) =P (Xt|St = 1)[
P (St = 1|St−1 = 0)P (St−1 = 0|Xt−1)
+P (St = 1|St−1 = 1)P (St−1 = 1|Xt−1)
] (5.4)
and
P˜ (St = 0|Xt) =P (Xt|St = 0)[
P (St = 0|St−1 = 0)P (St−1 = 0|Xt−1)
+P (St = 0|St−1 = 1)P (St−1 = 1|Xt−1)
] (5.5)
where and P (Xt|St) is from the two kernel estimators for cases (St = 1) and
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controls (St = 0). P (St|St−1) is the Markov chain for state transitions (see Table
5.2). P (St−1|Xt−1) is the probability distribution on St = 0 and St = 1 given data
up to t − 1 from Xt−1. Finally, as the previous equations were not normalised,
the probability of a case, given the data presented until this hour is defined:
P (St = 1|Xt) = 1− P (St = 0|Xt)
= 1−
P˜ (St = 0|Xt)
P˜ (St = 0|Xt) + P˜ (St = 1|Xt)
(5.6)
Thus, to begin a recursive process of obtaining a posterior probability for
sepsis states in time, an initial clinical guess for P (St−1 = 1|Xt−1) and P (St−1 =
0|Xt−1), is made using the kernel density estimates. Non-sequential data hours
are categorised using the kernel density estimates, while the HMM is used to
determine the posterior probability of sequential sepsis hours.
5.2.6 Repeated holdout estimate
Instead of the bootstrap estimate, a repeated holdout estimate is used. This
procedure randomly selects and holds out a portion of the training sample for
testing, and constructs a classifier with only the remaining sample [Kim, 2009].
The true error rate of the constructed classifier is estimated with the held-out
testing sample, and this whole process is repeated many times, and the average
of repeatedly obtained estimates of error rate is called the repeated holdout esti-
mate. In this study, one-fifth of the training sample is set aside for testing. The
holdout procedure is repeated 1000 times in this study.
Importantly, while the bootstrap estimate procedure would remove individual
data points, the repeated holdout estimate can be employed to remove individual
patients providing proper and contiguous time course data for training. One-fifth
data holdout and 1000 repetitions are fair comparison to the previously employed
bootstrap estimate used in both Chapter 3 and Chapter 4. Thus, a repeated
holdout estimate is used to preserve the time series of hidden state transitions
for testing and training the HMM.
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5.3 Results
5.3.1 Hidden Markov model
For hourly state transitions, 4286 hours contained SIRS and sepsis, while 1583
hours remained severe sepsis and septic shock. In addition, 66 hours saw a switch
from SIRS and sepsis to severe sepsis and septic shock and 74 hours switched from
severe sepsis and septic shock to SIRS and sepsis. Thus, the probability of SIRS
or sepsis switching to severe sepsis or septic shock in the next hour is 0.0152.
Alternatively, the probability of a severe sepsis or septic shock case to switch to
SIRS or sepsis the next hour is 0.0447. These values are summarised in Table
5.3. For both cases and controls, hour to hour, each tends to remain in the
same sepsis state. Thus, these values were used in Equations 5.4 and 5.5 for the
resubstitution estimate. For the repeated holdout estimate, these values changed
depending on the switching observed from the training set.
Table 5.3: Probability of hourly switching amongst cases and controls.
from control P (St = 0|St−1 = 0) = 0.9849 P (St = 1|St−1 = 0) = 0.0152
from case P (St = 0|St−1 = 1) = 0.0447 P (St = 1|St−1 = 1) = 0.9553
5.3.2 Resubstitution estimate
Table 5.4: Contingency table for resubstitution estimates
0.51 cutoff 1690 cases 4860 controls predictive values
positive tests 1608 193 PPV = 0.89
negative tests 82 4667 NPV = 0.98
performance measures sensitivity = 0.95 specificity = 0.96 AUC = 0.99
likelihood ratios LHR+ = 23.96 LHR- = 0.05 DOR = 474
At an optimal cutoff value of 0.51, the resubstitution estimate achieves 95%
sensitivity, 96% specificity, 23.96 LHR+, 0.05 LHR-, 89% PPV, 98% NPV, 0.99
AUC, and 474 DOR (Table 5.4). This clinically significant level of sensitivity and
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Figure 5.1: Subplot 1: ROC curve for the resubstitution estimate. Subplot 2: His-
togram of posterior probabilities normalised by cohorts. Subplot 3: Box and whisker
plot of posterior probabilities by independently scored sepsis cateogries (0: SIRS, 1:
sepsis, 2: severe sepsis, 3: septic shock).
specificity are sufficient to be routinely used in clinical practice [Pierrakos et al.,
2010]. A posterior probability result above 0.51 is obtained approximately 24
times more often from a patient case hour than from a control hour. Similarly, a
result below the optimal cutoff value is less than five-one-hundredths as likely to
be found in a case hour than from a control hour. Both LHR results at the optimal
cutoff value perform at a level that has the potential to alter clinical decisions
[Jaeschke et al., 1994b]. Both predictive values are also high. However, as a major
determinant of the predictive values is the prevalence of infection [Smith et al.,
2000], PPV and NPV alone do not reflect the test’s inherent accuracy. The 0.99
AUC shows high accuracy [Swets, 1988], and is near perfect. Finally, the DOR
also demonstrates this performance as a potentially useful test [Fischer et al.,
2003].
The ROC curve for the resubstitution estimate (Figure 5.1) shows overall high
diagnostic accuracy across all cutoff values. In particular, the clinically significant
level of 90% sensitivity is reached at a cutoff value of 0.84 while sensitivity is 99%.
Similarly, 90% specificity is reached at a cutoff value of 0.14, while sensitivity is
97%. Moreover, it can be observed that the majority of the ROC curve lies
within LHR+ and LHR- regions that have the potential to alter clinical decisions
[Jaeschke et al., 1994b].
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The histogram of the posterior probabilities normalised by cohort (Figure 5.1)
shows excellent discrimination between cases and controls, 90% sensitivity and
specificity cutoff values, and the optimal cutoff value. The box and whisker plot
of the posterior probabilities by sepsis class (Figure 5.1) shows 98% specificity
for SIRS, 95% specificity for sepsis, 92% sensitivity for severe sepsis, and 100%
sensitivity for septic shock. Thus, the resubstitution estimate demonstrates high
accuracy which is also independent of severity of illness.
LHR and MLR results for the resubstitution estimate are shown in Table 5.5.
Positive results obtained from 0.14–1 have the potential to alter clinical decisions,
while probabilities obtained above 0.03 often provide useful information, and
positive results below 0.01 rarely alter clinical decisions [Jaeschke et al., 1994b].
Negative LHR- results obtained from 0–0.83 have the potential to alter clinical
decisions, while probabilities obtained below 0.93 often provide useful informa-
tion, and negative results above 0.97 rarely alter clinical decisions [Jaeschke et al.,
1994b]. Amongst positive results obtained above the optimal cutoff value, val-
ues above 0.87 have the potential to alter clinical decisions, while values below
rarely change clinical decisions [Jaeschke et al., 1994b]. Finally, amongst nega-
tive results obtained below the optimal cutoff value, values below 0.12 have the
potential to alter clinical decisions, while values above rarely change clinical de-
cisions [Jaeschke et al., 1994b]. Thus, the majority of the resubstitution estimate
results have the potential to alter clinical decisions for the correct identification
of cases and controls. Finally, it should be noted that resubstitution is a best
case estimate. The results thus reflect that approach.
Table 5.5: Table of LHR regions and MLRs for the resubstitution estimate.
LHR+ 3 5 ≥ 10 LHR - ≤ 0.1 0.2 0.33
cutoff 0.01 0.03 0.14–1 cutoff 0–0.83 0.93 0.97
probability cases controls LHR+ probability cases controls LHR-
0.51–0.63 13 47 0.80 0.00–0.12 43 4349 0.03
0.63–0.75 26 38 1.97 0.12–0.25 16 165 0.28
0.75–0.87 71 56 3.65 0.25–0.38 15 98 0.44
0.87–1.00 1498 52 82.84 0.38–0.51 8 55 0.42
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Table 5.6: Contingency table for the repeated holdout estimate
0.14 cutoff 371856 cases 1088294 controls predictive values
positive tests 220491 420159 PPV = 0.34
negative tests 151365 668135 NPV = 0.82
performance measures sensitivity = 0.59 specificity = 0.61 AUC = 0.63
likelihood ratios LHR+ = 1.54 LHR- = 0.66 DOR = 2.32
Figure 5.2: Subplot 1: ROC curve for the repeated holdout estimate. Subplot 2:
Histogram of posterior probabilities normalised by cohorts. Subplot 3: Box and whisker
plot of posterior probabilities by independently scored sepsis categories (0: SIRS, 1:
sepsis, 2: severe sepsis, 3: septic shock).
5.3.3 Repeated holdout estimate
At an optimal cutoff value of 0.14, the repeated holdout estimate performs with
59% sensitivity, 61% specificity, 1.54 LHR+, 0.66 LHR-, 34% PPV, 82% NPV,
0.63 AUC, and 2.32 DOR (Table 5.6). This level of sensitivity and specificity is
not clinically significant [Pierrakos et al., 2010]. LHRs perform in regions that
rarely alter clinical decisions [Jaeschke et al., 1994b]. A 0.63 AUC shows low
accuracy [Swets, 1988]. Lastly, the 2.32 DOR shows that this test may not be
potentially useful [Fischer et al., 2003].
The ROC curve for the repeated holdout estimate (Figure 5.2) shows 0.63
AUC, which is a low accuracy [Swets, 1988]. The ROC curve reaches 90% speci-
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ficity at a cutoff value of 0.97, while sensitivity is 18%. Alternatively, sensitivity
only reaches 90% at a cutoff value below 0.01, while specificity is 0.00%. The ROC
curve lies in a within the region of rarely altering clinical decisions [Jaeschke et al.,
1994b]. The histogram of posterior probabilities normalised by cohorts demon-
strates the overlap between cases and controls. In particular, it can be observed
that more cases have a posterior probability near zero than one. The box and
whisker plot of posterior probabilities by sepsis class show that at the optimal
posterior probability cutoff value the test identifies 63% of SIRS, 61% of sepsis,
56% of severe sepsis, and 64% of septic shock. Thus, repeated holdout estimate
demonstrates low accuracy.
Table 5.7: Table of MLRs for the repeated holdout estimate.
probability cases controls LHR+ probability cases controls LHR-
0.14–0.35 32011 88191 1.06 0.00–0.03 107588 519286 0.61
0.35–0.57 25662 62488 1.20 0.03–0.07 24180 85754 0.83
0.57–0.78 29775 59957 1.45 0.07–0.10 9916 32125 0.90
0.78–1.00 133043 209523 1.86 0.10–0.14 9681 30970 0.91
The LHR regions for the repeated holdout estimate are not tabulated, as all
cutoff values were within the region of rarely altering clinical decisions [Jaeschke et al.,
1994b]. The MLR results for the repeated holdout estimate are shown in Table
5.7. The MLR LHR+ results are all over one, while MLR LHR- results are all
below one. Thus, the repeated holdout estimate represents the worst case esti-
mate where all MLR results are within regions that rarely alter clinical decisions
[Jaeschke et al., 1994b].
5.4 Discussion
5.4.1 Performance assessment
Across these estimates, the performance was very wide ranging. 59–95% sensitiv-
ity and 61–96% specificity spread from a near chance result to well into clinically
significant performance. With values of 1.54–23.96 LHR+ and 0.05–0.66 LHR-,
both of these metrics ranged from rarely altering clinical decisions to changing
clinical decisions. However, both measurements did not include one. 0.63–0.99
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AUC showed low to very high accuracy. 2–474 DOR ranged from not being a
potentially useful to test towards being a potentially useful test. This outcome
was visually represented in both ROC curves for the resubstitution estimate and
repeated holdout estimate, with a near perfect maximum performance, while
minimum performance resided in a performance range above random, yet not
altering clinical decisions.
Although the histogram for the resubstitution estimate showed very strong
discrimination, the repeated holdout estimate showed strong overlap between
cases and controls. Moreover, the proportion of cases with a posterior probability
towards zero was actually greater than those towards one. The box and whisker
plots discerned this further, where long tails were observed for all sepsis levels
for the resubstitution estimate. However, for the repeated holdout estimate, the
posterior probabilities for severe sepsis and septic shock had an interquartile range
spanning practically the entire range from zero to one.
Thus, many of the cases were misclassified as controls, while even some sepsis
controls had larger posterior probabilities. Likely, these misclassifications were
the result of patient hours that were difficult to adjudicate, more ambiguous than
clear cases and controls, and may have changed categorisation using either the
hierarchical and independent criteria. To examine this issue further, the HMM
was again tested using the hierarchical criteria as used in Chapter 3 (results not
shown), yet the HMM repeated holdout estimate results remained low, indicating
that this classification issue did not play a major role.
5.4.2 Methodology
Complete specification of a HMM requires the definition of its topology, the tran-
sition matrix, Q, for the hidden states, and the distributions of the observations
conditioned on each hidden state [Lee et al., 2006]. The topology defined for the
HMM used here had two hidden states: SIRS and sepsis controls and severe sepsis
and septic shock cases. For the purposes of dichotomous classification, this model
did not consist of four hidden states: SIRS, sepsis, severe sepsis, and septic shock.
This modeling choice effectively reduced of the number of transition probabilities
to be estimated, which can be important to curtail problems in the maximum
likelihood estimation procedures, such as over-fitting and local maxima in the
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likelihood function.
The transitions observed for hidden states is completely dependent on the
sepsis criteria chosen, either the ACCP/SCCM sepsis criteria [Bone et al., 1992;
Levy et al., 2003] or the independent criteria developed in Chapter 4. Both cri-
teria were tested, but only the independent criteria results were shown. Both
criteria categorisations used in the HMM obtained similar results for resubstitu-
tion and repeated holdout estimates. Thus, the transition probabilities do not
seem to greatly vary the HMM outcomes. Moreover, hourly step transitions can
be different amongst hospitals. Therefore, transition probabilities may not be the
most important term affecting the HMM.
The distributions of the observations conditioned on each hidden state, P (xt|St =
1) or P (xt|St = 0), were obtained by using the kernel density estimates from
Chapter 3. Kernel density estimates were used for the development of join prob-
ability density profiles for 213 hours of severe sepsis and septic shock cases and
5858 hours of SIRS and sepsis controls and for classification. A kernel probability
density profile was made for each cohort and for the clinical predictor. Thus, a
single density was used to encompass the predictors. As the results showed in
that work, kernel density estimates provided good estimates of class-conditional
observations.
After training, the model was ready to estimate hidden states using the re-
cursive HMM model equations primed with an initial clinician guess for the prior
probability that the patient hour was a sepsis case. The initial clinician guess can
be a chance result or based on knowledge available at that time. Thus, by utilis-
ing the kernel density estimates for initial clinical guesses and for non-sequential
hours in the patient record, the results show the additional information provided
from the HMM from the previous kernel density estimation classification results
for the independent criteria in Chapter 4.
5.4.3 Clinical significance
As explored in the results and discussion so far, the HMM reaches levels of clin-
ical significance for sensitivity, specificity, LHR+, LHR-, AUC, and DOR with
the resubstitution estimate results. However, the minimum performance demon-
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strated by the repeated holdout estimate is only represents low accuracy with the
AUC, while all other performance measures are not clinically significant. This
HMM result represents the greatest disparity between maximum and minimum
performance ranges and is the first time that the minimum results show a greater
proportion of cases to have posterior probabilities towards zero than one. Thus,
overall the HMM model’s clinical significance is indeterminate.
5.4.4 Limitations and next steps
To preserve the time dependency in testing and training, a repeated holdout
method was used to holdout patients rather than time points, as in the boot-
strap estimate. In this method, the patient-specific response and time course
of physiology and sepsis states impacts on the evaluation of the probability of
a case, given the patient data to that time point (Equation 5.4). A limitation
of this work may be that the time dependency in the model is much more sen-
sitive to inter-patient variability, and this patient sample population has high
inter-patient variability and low intra-patient variability. Yet, this notion may
prove eventually useful for the patient-specific monitoring and diagnosis of sepsis
patients.
The HMM assumes that the observations are conditionally independent given
the sequence of hidden states (Table 5.1). Thus, two observations at times t1 and
t2 should be independent if yt1 and yt2 are known. Notably, this assumption may
be the case for the observed physiological measurement timer series. Thus, the
HMM with two hidden states would be inadequate and a more complex topology
would be required, that considers other influences on the physiological variables,
such as medical treatment. A modelled relaxing the conditional independence
assumption is an extension of the HMM known as a Markov-switching model
[Lee et al., 2006]. Furthermore, a model including medical treatment which then
influences the hidden sepsis state due to antimicrobial treatment would poten-
tially extend this model further.
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5.5 Summary
A challenge in the early identification of sepsis is that infection is not always
clinically evident. Mathematical models can be used to help make inferences
about the observed physiology of a patient and link this to the unobserved clinical
status of sepsis state. 36 sepsis patient records were used to develop a HMM
to model these unobserved states of the patients, which were categorised upon
review.
A HMM was specified as a model with a two hidden state topology, an hourly
transition matrix using the labelled data defined by the independent sepsis criteria
in Chapter 4, and class conditional observations defined by the joint probability
density profiles for cases and controls using kernel density estimates from Chapter
3. Thus, the HMM was used to make inference about the sepsis state of the pa-
tient, given the observed time series of observed clinical predictors. In particular,
the model was updated recursively to provide a probability-based diagnosis of
the individual case history. The test result was compared to the labelled patient
record and diagnostic performance from the ROC curve was determined for the
resubstitution and repeated holdout estimate.
The HMM performed with 59–95% sensitivity, 61–96% specificity, 1.54–23.96
LHR+, 0.05–0.66 LHR-, 0.63–0.99 AUC, and 2–474 DOR. This wide range of low
to very high performance is conclusive but only clinically significant at maximum
performance levels. This HMM provides a next step in the evolution in the
design and evaluation of bedside clinical markers for a probability-based sepsis
diagnostic. However, the valuable contribution of this model in addition to the
previous model is limiting and once again issues of time dependency continue to
raise issues in the study design. Yet, future work, especially in refining the chosen
clinical predictors and definitions of the clinical stages may improve the model
and overall diagnostic performance.

Chapter 6
Conclusions
The research in this thesis presents the development of model-based diagnos-
tic tests for sepsis from a probability-based model to a patient-specific, time-
dependent model for accurate clinical decision support in real-time. A model
using kernel implementation of the Bayes classifier was used to develop class
conditional joint probability density profiles, given clinical measures of case and
control hours, and for classification. Classification accuracy was improved by
developing independent criteria that relaxed the ACCP/SCCM definitions to
mitigate misclassification bias and allowed more real-time classification along the
patient’s evolution in response to infection, treatment, and management. Finally,
a hidden Markov model was used to link patient data to the unknown sepsis state
and to incorporate time-dependency between sepsis states hour to hour recognis-
ing the time dependent evolution of disease. These model-based diagnostic tests
provided useful information for real-time clinical decision making and could be
developed further for incorporation into clinical studies and use.
Sepsis is common, costly, and often deadly, particularly amongst the elderly
and ill. Yet, despite the most modern medical treatment received in the medical
ICU, sepsis mortality remains high. It has been determined that the time to
initiation of effective antimicrobial treatment following sepsis-induced hypoten-
sion is the single strongest predictor of outcome over any form of treatment
[Kumar et al., 2006]. Studies have shown a reduction in sepsis mortality using
early goal-directed therapy [Rivers et al., 2001] and bundled treatment protocols
[Levy et al., 2010]. Yet, there remains a serious need for early, accurate, patient-
specific diagnostic test for severe sepsis to initiate life-saving treatment for the
reduction of sepsis mortality.
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Current sepsis diagnostic approaches include some combination of microbi-
ological, clinical, biochemical, and immunological evidence, yet there remains a
serious need for an accurate, real-time diagnostic for routine use in clinical care.
Blood culture is the gold standard test for microbiological confirmation of infec-
tion, yet results return only in retrospect in 24–48 hours eliminating any early
confirmation. In addition, false positive and false negative test results occur,
as not all organisms grow in vitro. Thus, a protocolised approach has been de-
veloped in consensus that is based on abnormal ranges of physiology, which, in
clinical experience, describes when a patient ‘looks septic’. The ACCP/SCCM
criteria are based on the hypothesis that SIRS, sepsis, severe sepsis, and septic
shock represent increasingly severe stages as an increasing severity of the systemic
inflammatory response to infection, and not necessarily the increasing severity of
infection. However, this approach is based on clinical experience and is not a
purely objective measure of the presence of disease.
Practically, application of the ACCP/SCCM criteria excludes patients with
confirmed infection and often results in heterogeneous classification even amongst
patients with confirmed infection. Thus, real-time use of the effective gold stan-
dard sepsis definitions lack real-time and accurate identification of sepsis given
the patient’s clinical observations at a single point in time. Moreover, the classi-
fication in time does not represent sepsis evolution in time, including response to
changing patient condition in response to infection and in response to treatment.
Finally, the criteria define generally abnormal ranges of clinical physiology, but
does not address high inter- and intra- patient variability of response. Thus,
sepsis diagnostics require patient-specific models including the clinical variables
most useful to represent patient state.
The necessary goals of sepsis diagnostics include early classification of sep-
sis patients and real-time patient specific monitoring of response to treatment.
Prognostic risk of mortality would also be clinically useful. However, as shown in
this research, none of these goals have been met given existing sepsis definitions
or diagnostic tools.
A challenge in the early identification of sepsis is that infection is not always
clinically evident. Mathematical models of physiological systems with clinical
data can be used to determine patient-specific model-based insulin sensitivity
(SI), which has been shown to relate to patient sepsis state. Model-based SI with
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readily available bedside clinical data together as a multivariate clinical biomarker
have improved the diagnostic performance. This work has significantly extended
these results to provide a probability-based diagnostic test for classification of
sepsis in real-time, given the patient’s clinical measures at that point or even up
to that time point, and done so in the presence of realistic incidence rates by
hour.
Kernel density estimation using a Bayes classifier was successfully imple-
mented for the development of class conditional joint probability density profiles
for 213 hours of severe sepsis and septic shock cases and 5858 hours of SIRS
and sepsis controls and for classification. This method provided a probability-
based diagnostic approach, given clinical measures such as model-based insulin
sensitivity (SI), temperature, heart rate, respiratory rate, and blood pressure for
a real-time diagnosis of sepsis. The classifier performed with the greatest sta-
bility and accuracy when using the product kernel, 0.5 prior probabilities, and
Cholesky transformation. Optimal performance results were 0.78 (0.69–0.94) sen-
sitivity, 0.83 (0.76–0.94) specificity, 0.87 (0.78–0.99) AUC, 0.10–0.36 PPV, 0.99–
1.00 NPV, 4.48 (2.88–15.70) LHR+, 0.27 (0.06–0.41) LHR-, and 16.83 (7.04–262)
DOR. Thus, the classifier showed good discriminative ability, often provides use-
ful additional information for clinical decision making, increased accuracy with
greater posterior probabilities, and independence from disease severity. The de-
veloped classifier can be readily assessed at the bedside to yield a non-invasive
and continuous estimate of sepsis state to provide an accurate rule-in and rule-
out measure and monitoring of interventions in real time for support in clinical
decision making for sepsis diagnostics.
Thus, this work, as an extension of the work done previously by Blakemore et al.
[2008] and Lin et al. [2011a], presents the use of model-based insulin sensitivity
as a patient-specific parameter useful as a sepsis predictor. Moreover, this repre-
sents a probability-based sepsis diagnostic in real-time with the potential to often
provide useful clinical decision support.
An independent sepsis criteria was defined to re-categorise sepsis patient
hours to mitigate misclassification bias observed while using the ACCP/SCCM
definitions. The existing ACCP/SCCM definitions are hierarchical and require
microbiological confirmation and concurrent observations of abnormal physiology.
However, categorisation of sepsis in real-time using these definitions is erratic
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and often reflects misclassification, heterogeneous categorisation, and exclusion.
Therefore, an independent sepsis criteria was defined where sepsis categories are
evaluated independently, then summed. Thus, this categorisation defined 1690
hours of severe sepsis and septic shock cases and 4860 hours of SIRS and sep-
sis controls. Kernel density estimates were used for the development of joint
probability density profiles for each cohort and for classification. Optimal per-
formance was achieved at 86% (81–94%) sensitivity, 85% (79–95%) specificity,
0.92 (0.88–0.99) AUC, 6 (4–18) LHR+, 0.17 (0.06–0.24) LHR-, 57–86%) PPV,
92–98%) NPV, and 34 (16–300) DOR at a posterior probability cutoff value of
0.49, therefore high accuracy as a potential severe sepsis diagnostic.
Hence, application of the independent criteria for categorisation in real-time
provides a smoother, more realistic time-varying signal for classification, includ-
ing plateaus of IV treatment, and improved diagnostic performance. Relaxation
of the assumptions of the ACCP/SCCM hierarchical criteria to independent cat-
egorisation show that any symptom contributes as evidence of sepsis. Notably,
there is an inherent trade-off between misclassification bias and case-control bias
in this study. However, because the difference between the cases and the controls
used in this study will be smaller than non-diseased controls, this choice results
in a lower statistical power to detect an exposure effect. Equivalently, this choice
also presents a much stricter, rigorous, and clinically realistic test of the classifier.
Finally, a hidden Markov model (HMM) was used to make inference about the
observed physiology of a patient and link this to the unobserved clinical status
of sepsis state as well as to introduce time-dependency between sepsis states.
The HMM is completely specified by its topology, the transition matrix for the
hidden states, and the distributions of the state conditional observations, which
were determined from the 1690 hours of cases and 4860 hours of controls using
the independent criteria. The HMM performed with 59–95% sensitivity, 61–96%
specificity, 1.54–23.96 LHR+, 0.05–0.66 LHR-, 0.63–0.99 AUC, and 2–474 DOR.
This study observed that the performance of the HMM was similar for both
the ACCP/SCCM definitions and the independent criteria. Thus, the state tran-
sition probabilities are shown to be independent of categorisation definitions.
Lastly, the observed clinical signs are linked to hidden state, yet are most accu-
rate when the model is trained on the patient data. Thus, the HMM has the
most potential as a patient-specific model to reduce the variability due to inter-
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and intra- patient variability.

Chapter 7
Future works
7.1 Design considerations
In this case-control study, only one data set was available for both training and
testing of the classifier using the resubstitution, bootstrap, .632+ bootstrap, and
repeated holdout estimators. However, for classification, it is important to test
the developed classifier on an independent set of testing samples to estimate the
true error rate of the classifier. Future work should include data collection from
sepsis patients in an independent ICU to be used as testing samples for evaluation
of the diagnostic performance of the classifier developed in this work.
This work consisted of a study population of only sepsis patients distinguished
by their categorised sepsis case hours and non-sepsis control hours. However, a
diagnostic test for use in critical care should better represent clinical reality. In
particular, the study population should reflect a greater spectrum of diseases, as
a clinician requires help of a diagnostic test for clinical decision support exactly
for the ambiguous cases. Therefore, future studies should include patients with
both infectious and non-infectious causes of SIRS, organ dysfunction, and shock
to more reflect the greater spectrum of alternative differential diagnoses. Further-
more, a diagnostic test should be applicable to a clinician’s patient population –
and this approach would be more broadly transferrable not only patient popula-
tions in the ICU, but also in the ER. Future work may include data collection in
the ER and ICU of both infectious and non-infectious patients with SIRS, organ
dysfunction, and shock.
In this work, the ACCP/SCCM sepsis criteria scored independently, rather
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than hierarchally, captured the more staged and clinically observed evolution of
sepsis over time, including plateaus of septic shock during administration of IV
fluid resuscitation in real-time. The ACCP/SCCM definitions do provide clin-
ical thresholds of abnormal ranges, but they do not allow similar prediction in
sepsis diagnostics, in particular, to the dynamic patient evolution in response to
infection. Thus, the sepsis categorisation criteria should be evaluated further, in
particular, by evaluating which clinical measures are most useful for sepsis clas-
sification in time. The contribution of each clinical predictor towards diagnostic
accuracy should be evaluated, specifically model-based SI .
7.2 Methods considerations
Kernel density estimation (KDE) was used in this study to develop a classifier for
real-time identification of severe sepsis. The resulting distribution of posterior
probabilities for sepsis cases using the KDE bootstrap estimates was uniform,
while the controls were positively skewed. Alternatively, use of the independent
classification criteria resulted in improved discrimination, where the posterior
probability distribution of the cases became negatively skewed. Thus, although
the criteria applied the same ranges to define abnormal physiology, the cate-
gorisation of cohorts scored independently, rather than hierarchically, resulted in
distinct observations of clinical physiology, which discriminated cases and con-
trols. Therefore, a limitation of the application of the ACCP/SCCM criteria
applied in real-time is a problem of sampling frequency, which requires abnormal
clinical signs to occur at the same time. Alternatively, the KDE model assumes
independence of both sepsis states and clinical physiology in time and using the
independent classification relaxes this assumptions of the ACCP/SCCM criteria.
Thus, any clinical signs of abnormality are useful to identify sepsis when taking
any sample in time. Future work may include using the KDE classifier with inde-
pendent criteria as inclusion criteria to identify patients meriting further sepsis
observation.
The hidden Markov model (HMM) was used to make inference about the
sepsis state of a patient, given an observed time series of clinical predictors and
was updated recursively to provide a probability-based diagnosis of individual
case history. In particular, the posterior probability distributions of the repeated
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holdout estimate for cases and controls were similar, each with bimodal peaks at
probability values of 0 and 1. Classification criteria did not impact the results,
therefore transition probabilities do not greatly vary the HMM outcomes. There-
fore, as transition probabilities likely vary at different hospitals under different
sepsis treatment and care, this would likely not impact classification outcomes.
Thus, the HMM offered the most potential for future use in alternative clinical
settings. Moreover, it is important to note that the probability to stay in a state
decreases exponentially, which may not reflect reality properly. A more appropri-
ate behaviour to approximate would be the probability distribution for staying
in a state, and a method for this should be examined.
The HMM resubstitution estimate provided the best discrimination between
cases and controls observed in this work, while the HMM repeated holdout es-
timate resulted in the greatest overlap of the posterior probability distributions
between cases and controls. Thus, when using a model with time-dependence, the
greatest impact on test outcome is not the criteria used, but training the classifier
on the individual patient-specific physiological signs as baseline and in response
to infection in time, given the patient data at that time point. Therefore, the
HMM offers the most potential for patient-specific monitoring and diagnosis of
sepsis patients in real-time. Future work using the HMM should include devel-
oping patient-specific models from observed patients identified using the KDE
classifier for diagnosis of sepsis, monitoring response to therapy, and evaluating
risk of mortality.
Furthermore, there is an argument about the number and even existence of
sepsis states. One one hand, in a HMM, the number of states can be learned and
this would allow a critique of the states defined by the ACCP/SCCM definitions
as well chosen or not. On the other hand, the main argument between ‘states’
and ‘non-states’ is the nonlinearity in the probability distribution of the variables.
A state implied a time stay at the neighborhood of the variable – a sharp peak in
the distribution density function. Cluster analysis can be used to verify that an
observation of some clinical signs are more likely than others for the construction
of sepsis states. However, a method is needed to incorporate the time structure
of the observations as the probability density functions are superseding in time.
Future work should include verifying if models like the HMM can verify the
number and existence of sepsis states.
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7.3 Model considerations
Finally, work should include the development of other Markov models for use in
sepsis diagnostics. The HMM assumes that clinical observations are conditionally
independent given the sequence of hidden states (see Table 5.1). A model relaxing
the conditional independence assumption is an extension of the HMM known as
a Markov-switching model. Furthermore, a model including other influences on
physiological variables, such as medical and antimicrobial treatment, which then
influences the hidden sepsis state would potentially extend this model further.
7.4 Summary
Thus, future work towards developing an accurate, real-time, patient-specific
model for sepsis diagnosis includes examination of the independence of clinical
criteria for classification, selection of which clinical predictors are most useful
for making a correct diagnosis, and model development based on the individual
patient. Work should be made towards development of a model incorporating
time dependence, the number and existence of states, and the probability distri-
bution of staying in these states. Finally, this model could be extended for use
not only to diagnose sepsis states, but also incorporate prognosis by predicting
risk of mortality or recovery by involving ’surviving’ or ’deceased’ classes.
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